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ABSTRACT 
The ligating property of DNA has been theoretically investigated from the 
structural and electronic point of view in this thesis. A series of short segment DNA 
models in solvent was studied using a novel hybrid Molecular Dynamics + Quantum 
Mechanics (MD+QM) method. The hybrid method was demonstrated to be highly 
applicable for the studied systems by comparing the calculated results with the 
experimental data. Based on the calculated results, a set of empirical rule which locates 
the two most active sites in DNA sequences leading to postulation of cisplatin-DNA 
crosslinks was proposed. The rule was extremely successful when applied to the 
experimental sequences. Then the four experimental cisplatin-DNA adducts were 
carefully examined structurally and a better understanding of the interaction between 
cisplatin and DNA was deduced. Some other applications of the calculated results were 
also briefly discussed in the thesis. 
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摘要
本论文从结构学和电性质的角度，在理论上研究了脱氧核 
糖核酸（DNA ) 的结合性质。一种新型的M D+Q M杂化理论 
计算方法被采用，借以研究一系列在溶液中的短序列D N A模 
型。通过计算值和实验值的比较，这种杂化理论计算方法对所 
研究系统的高度适用性被证实。在计算结果的基础上，提出了 
一系列经验性的规律来定位D N A 序列中最高活性的二个位 
点 ，借以预测顺二氯二氨基铂与D N A的结合产物。这些规律 
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Deoxyribonucleic Acid (abbreviated D N A ) is a nucleic acid that contains the 
genetic instructions used in the development and functioning of all known living 
organisms and some viruses. It was first isolated by the Swiss physician Friedrich 
Miescher who, in 1869, discovered a microscopic substance in the pus of discarded 
surgical bandages. As it resided in the nuclei of cells, he called it "nuclein" (1). In 1919 
Phoebus Levene identified the base, sugar and phosphate nucleotide unit and suggested 
that D N A is consisted of a string of nucleotide units linked together through the 
phosphate groups (2). However, Levene thought the chain was short and the bases 
repeated in a fixed order. In 1937 William Astbury produced the first X-ray diffraction 
pattern which showed that D N A had a regular structure (3). But until 1953, what is now 
accepted as the first accurate model of D N A structure was not suggested in the journal 
Nature by James D. Watson and Francis Crick based on X-ray diffraction images taken 
by Rosalind Franklin and the information that the bases were paired (4). Experimental 
evidence for Watson and Crick's model were published in a series of five articles in the 
same issue of Nature. Due to the great contribution, Watson, Crick and Wilkins jointly 
received the Nobel Prize in Physiology or Medicine in 1962. 
Nowadays it's known that D N A structures are more complicated and multiform. It 
bears a variety of secondary and tertiary structures such as hairpins, bulges, branched 
junctions, two-dimensional lattices, three-dimensional cubes and octahedrons (5, 6) 
depending upon the conditions. It's also known that many diseases resulted from 
malfunction, mutation or damage of D N A such as Downs syndrome, phenylketonuria, 
hemophilia, skin cancer and so on. To get insights into biological functions of nucleic 
acids and a deeper understanding of those diseases, the structure characteristics and some 
chemical properties of D N A were investigated in this thesis. 
1.2 Deoxyribonucleic Acid 
D N A is composed by two long strands of simple units called nucleotides. The two 
strands run in opposite directions to each other and are therefore anti-parallel (Figure 1.2). 
A nucleotide consists of a deoxyribose sugar, a heterocycle base and a phosphate group 
(Figure 1.1). The sugar part and the phosphate group part, connected by phosphodiester 
bonds, are usually called "Backbone of DNA". The heterocycle base (Figure 1.3) is 
connected to CI, position of the sugar ring and the complementary bases are held together 
by hydrogen bonds to form base pairs, whereby adenine (A) pairs with thymine (T) and 
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guanine (G) with cytosine (C) (Figure 1.4). It is the different combinations of these four 
bases along the backbone that encode different genetic information. 
In general, D N A is divided into three categories, right-handed A- and B- forms, 
and left-handed Z-form (Figure 1.5) (5). The Waston-Crick model structure is referred 
the B-form DNA, which is the most stable form under physiological conditions and 
therefore it was chosen as our study model. 
Figure 1.5 Structures of A-，B- and Z- form D N A (From Left to Right, Respectively) 
To describe D N A structures conveniently and efficiently, some geometric 
parameters were introduced. Among them two kinds of parameters, the torsion angles and 
the helical parameters, are most important. The torsion angles describe the conformation of 
sugar-phosphate backbone. All of them, namely a , p, y, 5，s,专 and u。，，u�，1)3，U4, as 
well as the orientation of the base x，are defined as shown in Figure 1.6. The conformation 
of sugar ring, however, is usually described by another term, the pseudorotation phase 
angle P [1-1], which is given rise to the endocyclic torsion angles of sugar. Values of phase 
angles from 0° to 360° are given in multiples of 36° and hence ten conformations 
included (Figure 1.7). 
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Figure 1.7 Definition of the Pseudorotation Angle (7) 
The other most important kind of parameters, the helical parameters, are utilized to 
describe the geometry of nucleic acids.Totally 16 defined parameters are included 
according to the E M B O workshop (8). They are divided into two categories according to 
their motion modes, namely rotation mode and translation mode. Rotation mode includes 
the inclination (R|), tip (6), buckle (K), propeller twist (co), opening (o), tilt (x), roll(p) and 
twist (Q). Translation mode includes x displacement (dx),y displacement (dy), shear (Sx), 

















displacement (dx) y displacement (dy) Shear (Sx) 
Shift (Dx) Slide (Dy) 
Stretch (Sy) 
Rise (Dz) 
Figure 1.8 Definitions of the Helical Parameters 
1.5 DNA Studies 
D N A is so important that study on D N A is always of scientists' interest since the 
day on which it was discovered. An enormous body of experimental and theoretical data 
had been reported over the years (6，9, 10). Usually the experimental data comes from X-
Ray and N M R trials, and after obtaining the structure coordinates from experiments, 
theoretical investigation were carried out. 
It's revealed that guanine's ionization potential (IP) is the lowest among the four 
bases (Table 1.1). Therefore guanine (G) shows the most electron donating property and is 
most easily oxidized. In the presence of oxidants or under U V irradiation, G is readily 
oxidized and ultimately forms 8-oxoguanine (or dihydro-8-oxoguanine) (11-13)，which 
leads to mutation during replication (14). In addition, since G-rich sequence is more 
electronegative, as demonstrated by the lower IP values of consecutive G (i.e. GG, GGG, 
G G G G ) comparing with that of single G (Table 1.1)，the positive charge of G radical 
cation (G+ ) can migrate to the G-rich position in the sequence through charge transfer 
(Figure 1.9). And consequently, the mutational hot spot changes. 
For a G-rich sequence, the 5,-G is more electronegative than the 3'-G, which is 
demonstrated by the fact that the Highest Occupied Molecular Orbital (HOMO) of stacked 
contiguous G is largely localized on 5'-G (12, 13, 16). However, in some cases, such as 
TGGGT, M O analysis indicates that the center G is the most reactive (17). It's suggested 
that the reactivity ofDNA is a property of sequence dependence. 
Table 1.1 Ionization Potential ofN-Methylated Nucleobase Monomers and Stacked 
Contiguous Guanines (eV) (15) 
Base G A C T G G G G G G G G G 
IP (eV) 7.75 8.24 8.8 7 9.14 7.28 7.07 6.98 
(0.47)* (0.68)* (0.77)* 




Figure 1.9 Oxidation of G and Charge Transfer to G G 
G-rich sequences and oxidative damage are very important in biological systems, 
whereby the reactivity and the sequence pattern are highly related. G, especially, plays a 
key role in D N A damage. It's suggested that drug design to treat genetic diseases can be 
targeted towards the reaction with D N A bases. Further, understanding the structural and 
10 
electronic properties of D N A is expected to assist in the recognition of the biological 
targets (18). 
1.4 Cisplatin Studies 
Cisplatin (Figure 1.10a) is a widely used anticancer drug that has been particularly 
successful in treating small cell lung, ovarian, testicular, head, and neck tumors (19). Since 
its anticancer activity was discovered by Rosenberg et al. in 1969 (20), Pt complexes have 
received much attention for their antitumor effect. Nowadays, although other anticancer 
drugs eventually take the place of cisplatin for their relatively low nephrotoxicity and 
drug-resistant, it is still used as a benchmark for new drugs (21). Due to this, it was chosen 
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Figure 1.10 (a) Cisplatin and (b) Transplatin 
During the last 40 years, much progress has been made in understanding cisplatin's 
mode of action. Many details of the mechanism leading to antitumor activity have been 
well established (22-24). N o w it's widely accepted that cisplatin's antitumor activity comes 
-11 -
from its binding to D N A and thus leading to an overall curvature of the D N A double helix. 
The distorted D N A then binds to the high mobility group (HMG) domains of proteins, 
impeding replication and cell repair processes, leading eventually to cell death (25). 
In view of the case of D N A binding, there have been many studies of the reaction 
between cisplatin and D N A bases. N o w it's certain that cisplatin firstly binds to the N7 site 
of purines, and prefers guanine over adenine. Platination to two purines gives the D N A -
adducts with intrastrand and interstrand crosslinks. Experimentally, it's known that the 
bridged structure consists of 65% l，2-d(GpG) intrastrand, 25% 1,2-d(ApG) intrastrand, 
and the rest other bridged structures like l，3-d(GpXpG) intrastrand, the d(GpC)d(GpC) 
interstrand etc. Interestingly, the adduct of 1,2-d(GpA) intrastrand is hard to find (26, 27). 
Binding of cisplatin had been shown to take place on the A of the 5’ side of d(ApGpA) 
(28). It's suggested that the failure to yield cisplatin-d(GpA) bridged product is due to the 
slow monoftinctional binding of cis-[PtCl(NH3)2(H2 0);r, whereby the binding is the 
slowest when compared to that of G G or A G (29). 
The anticancer activity of cisplatin as mentioned above comes from its binding 
with purines of D N A and leading to a structural distortion of the D N A and finally causing 
cell death. In the past years, scientists did a lot of work to theoretically investigate the 
mechanism of the binding of D N A with cisplatin. Maybe due to the huge molecular weight 
-12-
of whole D N A and thus the huge computational cost, however, most of the theoretical 
studies focused on the interaction between cisplatin and single base, single base-pair or 
just a few base-pairs, and most of the work even excluded the sugar-phosphate backbone 
out of their scope. To mimic a more realistic situation, it's very necessary to construct a 
case of longer D N A sequences, including sugar-phosphate backbone, solvent effect, 
electrostatic effect etc. 
1.5 Scope of the Thesis 
Fu did a meaningful job on theoretically investigating the structures and the 
electronic properties of DNA, and its ligating properties with cisplatin, as well as the 
factors controlling the formation of the binding products (18). In her study, a series of 
short segment DNA, namely, 5’-GX-3’�5’-AX-3,, 5’-XGG-3’�5'-GGX-3', 5’-GXG-3’�5'-
XAG-3’�5’-AXA-3'’ 5'-XGGX-3', were optimized and studied using ab initio method in 
gas phase. As a conclusion, she showed that H O M O localizes on G for any G-containing 
D N A sequence. In addition, a set of empirical selection rules was suggested for identifying 
the locations of H O M O in D N A sequences. Further, she found the chelation of cisplatin is 
selective and sequence-dependent (18). 
However, all of her work were based on the optimized structures of D N A models at 
the RHF/ST0-3G level of theory in gas phase. It suffers from some disadvantages. Firstly, 
-13 -
the realistic biochemical environment of D N A is more complicated than in gas phase. Not 
only longer D N A sequences is needed, but also many effects such as solvent effect, 
electrostatic effect etc. should be considered. Thus the results obtained in gas phase may 
be not accurate enough to draw practical conclusions. Secondly, the basis set STO-3G used 
is the simplest basis set. It is necessary to use a more advanced basis set when dealing with 
the situation with various effects (such as polar effect etc.). Moreover, ab initio method 
(such as RHF) is computationally demanding and time consuming (i.e. very expensive) 
and thus not suitable for the computation of realistic systems. Subsequently, alternative 
time saving strategy needs to be developed. 
Nowadays, a number of computational methods are available whereby some of 
these methods have been modified to handle large system (30-35). Unfortunately, some of 
the DFT based methods, e.g. plane wave DFT (31) cannot be used in the M O analysis as 
they cannot be used together with N B O methods. For the structure optimization, although 
new DFT (32) and semi-empirical (34) methods are available, benchmark testing (accuracy 
vs. time) as to the suitability to the large systems has not been carried out. In this project, a 
hybrid Molecular Dynamics + Quantum Mechanics ( M D + Q M ) method (25, 36-37) was 
utilized. D N A models, as well as the solvent molecules (water) and the counter ions (Na + � 
to neutralize the system), were firstly equilibrated (optimized) using molecular dynamics 
-14-
(MD) method; after then M O analysis was carried out with quantum mechanics (QM) 
method and relative information was then derived or deduced. 
The ultimate goal of this project is to re-examine the set of rules proposed by Fu 
(18) which uses an established chemical basis to predict the formation of Pt-DNA lesion. 
In Chapter 2，computational details were given and the applicability of the M D + Q M 
method was discussed. In Chapter 3, the H O M O and H O M O - 1 (the next Highest Occupied 
Molecular Orbital) location obtained by the proposed computation strategy, of the series of 
short segment D N A adopted in Fu's thesis (18)，was re-examined and analysis was then 
followed. Moreover, the analysis would be extended to systems with 5 to 8 base pairs, 
especially sequences with pure G such as G G G G G， G G G G G G , G G G G G G G , 
G G G G G G G G . This can particularly shed light on the electronic preference of G1-G2 
binding versus of G1-G3 binding. The possible reaction between cisplatin and those D N A 
models would be also discussed from structural point of view in this chapter. Then in 
Chapter 4，the obtained results would be summarized and some conclusion would be 
drawn for the investigation work. 
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CHAPTER T W O 
METHODOLOGY AND COMPUTATION 
2.1 Introduction 
Nowadays, much computer-based software had been developed in computational 
chemistry. However, looking for an appropriate approximation is still a preoccupation to 
quantum mechanical calculation. As stated in Chapter 1，a hybrid Molecular Dynamics + 
Quantum Mechanics ( M D + Q M ) method was utilized in this project. Details of the 
method are described as follows. 
2.2 Molecular Dynamics Simulation 
Molecular Dynamics (MD) is a simulation of the time-dependent behavior of a 
molecular system. It uses molecular mechanics (MM) method to compute the energy of a 
system. The information about possible energy levels and conformations could be 
obtained by this method (38’ 39). 
A M B E R software was used to run M D of the D N A models in this work. 
Generally, A M B E R refers to two things: a set of molecular mechanical force field for the 
simulation of bimolecular and a package of molecular simulation program which includes 
source code and demos. Here the latter meaning is referred. The version of the A M B E R 
program used in this work is version 9, which was released by University of California, 
-16-
San Francisco (UCSF) subject to a licensing agreement (40). The computational 
procedures as well as the details are listed as follows. 
The initial structures of the D N A models in B-form double helix were constructed 
with the nucgen script in A M B E R package. Noting that D N A models are anions due to 
the ionized phosphate groups, tleap script was subsequently adopted to neutralize the 
systems using sodium counter ions. A truncated octahedral box of water, TIP3PB0X, 
around the D N A models with the radius of 8 A, was then created. The topological files 
and the coordination files were saved for the next minimization process. 
The minimization process includes two stages. During the first stage D N A 
molecular, excluding the sodium ions and the water molecules, was fixed using a 500 
kcal mol"' • A"^ force constant. Particle Mesh Ewald (PME) method in conjunction with 
constant volume periodic boundaries was used to calculate long range electrostatic 
interaction, with a cutoff of 10 A. 500 steps of steepest descent minimization followed by 
500 steps of conjugate gradient minimization were then carried out. After completion the 
first stage ends up and the second stage shall start. During the second stage, the entire 
system was minimized. N o component was fixed this time and just let the whole system 
relax. 1000 steps of steepest descent minimization followed by 1500 steps of conjugate 
17 
gradient minimization were then carried out. After completion, the whole minimization 
process was accomplished and the next molecular dynamics process was followed. 
The molecular dynamics (MD) process also includes two stages. During the first 
stage the system was heated from 0 K to 300 K with weak restraints on the solute. 
Random initial velocities from a Boltzmann distribution were then generated and 
coordinates from the coordination files were read. P M E method in conjunction with 
constant volume periodic boundaries was used. SHAKE keyword was turned on to 
constrain bonds involving hydrogen. The langevin dynamics was used to control the 
temperature with a collision frequency of 1.0 ps"'. 10,000 molecular dynamics steps with 
2 fs per step were carried out, to give a sub-total simulation time of 20 ps. 
After successfully heating the system at constant volume with weak restraints on 
the DNA, it is necessary to switch to constant pressure (1 atm, isotopic position scaling 
was used to maintain the pressure, and 2 ps relaxation time was needed) so that the 
density of water can relax. Meanwhile, since it is already at 300 K, the restraints on the 
D N A can be safely removed. 100 ps was allotted for the second stage, namely 
equilibration stage to give the whole system plenty of time to relax. 
18 
M D simulation was accomplished after completion of all above procedures. 
Before going on, however, it is essential to check whether equilibrium has been 
successfully achieved or not. A number of system properties, namely volume, density, 
temperature, pressure, total energy, kinetic energy, potential energy and root mean square 
deviation (Rmsd), were selected to be examined. Figure 2.1 shows the results of a 
selected D N A model (GGG) from the simulations. 
Notice how the volume of the system initially decreases as the water box relaxes 
and reaches a stable value (Figure 2.1). Smooth transitions in the plot followed by the 
slight oscillations around a mean value suggest the equilibration process was successful. 
So is the situation of the density of the system. It's a mirror of the volume. The system 
was lastly equilibrated at a density of about 1.02 g/cm ^. It is reasonable. Note that the 
density of pure liquid water at 300 K is approximately 1.00 g/cm ^. Adding a 3-mer D N A 
and associated charges has increased the density by around 2%. 
19 
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Figure 2.2 Temperature (Left) and Pressure (Right) against Time Plots throughout the 
Simulation 
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Figure 2.3 Energy (Left) and Rmsd (Right) against Time Plots throughout the Simulation 
For the temperature of the system (Figure 2.2)，it increased from 0 K to 300 K 
during the first 5 ps and then remained almost constant. It indicates that the use of 
Langevin dynamics for temperature regulation was successful. The situation is a little 
different for the pressure of the system (Figure 2.2). During the first 20 ps the pressure 
remains zero. This is expected since a constant volume simulation was running in which 
the pressure wasn't evaluated. At the time point of 20 ps it was switched to constant 
pressure, allowing the water box to relax. The pressure immediately dropped sharply and 
became negative. From 20 ps to 40 ps, the pressure fluctuated wildly. But after 50 ps, the 
21 
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pressure eventually approached around latm. This validates that the equilibration was 
achieved. 
In the energy plot (Figure 2.3)，the red line, the blue line, and the black line 
represent the kinetic energy (KE), the potential energy (PE) and the total energy (E), 
respectively. It's noted that all of the energies increased during the first few picoseconds, 
corresponding to the heating event from 0 K to 300 K. The kinetic energy then remained 
constant for the rest time. It implied that the temperature thermostat program, which 
directly decides the kinetic energy, worked correctly. The potential energy, and 
consequently the total energy, initially increased and then stayed constant during the 
constant volume stage (0 to 20 ps). As it was switched to constant pressure, the PE and 
the E of the system decreased a little (20 ps to 50 ps) and then leveled off for the rest time 
(50 ps to 120 ps). In the Rmsd plot (Figure 2.3), it was seen that the Rmsd of the D N A 
backbone atoms remained low due to the restraints on D N A for the first 20 ps. After 
removing the restraints the Rmsd shot up as the D N A relaxed within the solvent (20 ps to 
50 ps). After that the Rmsd is fairly stable with no wild oscillations (50 ps to 120 ps). 
All the results suggested the simulation was successftil. One can also take a look 
at the trajectory file to observe how the dynamics of the D N A molecules changed 
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throughout the simulation. This may also offer some additional clues for the quality of 
the simulation. 
After completing all of this, it's ready to proceed to the next process, the quantum 
mechanics calculation. 
2.3 Quantum Mechanics Calculation 
Although molecular dynamics simulation is fast and time-saving, it suffers from 
several limitations such as requiring extensive parameters, inaccurate energy value and so 
on. It is still necessary to use it with the combination of the quantum mechanics method. 
Although some research groups had successfully applied SCF, MP2, DFT 
methods to the study of the D N A base pairs (21，24，25, 41-44), while other groups used 
Fragment Molecular Orbital (FMO) scheme to treat large scale molecules (45-47)， 
Hatree-Fock method (HF)�however, remains the primary method of the choice. This is 
on the one hand due to its lower computational cost (compared with SCF, MP2, DFT 
methods); on the other hand making the comparison of the data with that obtained using 
pure HF method reasonable. 
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The applicability of HF method for D N A models had been discussed by Fu (18) 
and won't be presented here. Except for the computational method, the choice of basis 
function is also important. Generally speaking, the larger the basis set, the more accurate 
the results, but meanwhile the more expensive the computation. Due to the limitation of 
current computational resources, 3-2IG basis set is ultimately chosen. Considering the 
polarization effect, 6-3IG* basis set is adopted for the phosphorus atom (P) separately. 
Since there are too many atoms (up to some thousands) in the system, it's almost 
impossible to carry out an ab initio calculation. Therefore water molecules were tripped 
from the system after molecular dynamics simulation process. To get the optimized 
structure, the coordinates from 50 ps to 120 ps of the molecular dynamics was averaged 
since there is no wild fluctuation for Rmsd value (Figure 2.3) during this period. To 
neutralize the system, sodium ions (Na + ) were kept. For simplification, only singlet 
states of D N A models were considered. 
A single point energy (SPE) calculation was first done. Then, to elucidate the 
electronic properties of the DNA, the H O M O and H O M O - 1 were located. All of the 
quantum mechanics calculation was performed using Guassian03 program (48) at 
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RHF/GEN (3-2IG for C, H, 0’ N, Na; 6-3IG* for P) level of theory using PC clusters 
and workstations. 
2.4 Verification of Methodology 
To verify the method utilized, it is necessary to compare the results with the 
experimental data. Fu suggested three parameters, namely the backbone torsion angle, 
N7-N7 distance and the location of H O M O for the verification (18). Here her suggestion 
was adopted and the comparison details for each parameter are listed below, 
2.4,1 Backbone Torsion Angles 
The sugar-phosphate backbone torsion angles of the optimized three base-pair 
structure 5'-GGG-3' and four base-pair structure 5-GGGG-3', were compared with the 
experimental results obtained from the Nucleic Acids Database (NDB) (49). Structures of 
47 sequences determined using X-ray (50) and 12 sequences determined using N M R (51) 
containing the G G G fragment were extracted for comparison (Appendices I and II). 
Moreover, to have a comparison between the results calculated in solvent and those 
calculated in gas phase, the points obtained by Fu (18) were also plotted. 
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For the case of 5,-GGG-3', it was found that all the torsion angles match the 
experimental data well (Figure 2.4). So is the case of 5'-GGGG-3' (Figure 2.6). Since one 
phosphate group per strand was omitted when D N A models were constructed by the 
A M B E R program or SYBYL 6.2 program in Fu's study (18)，some parameters, i.e. 
a, p, 8, 4 of the 3'-end base such as the third base of 5'-GGG-3' were not available. To 
partly validate whether the parameters of the third base match the experimental data or 
not, a comparison between the parameters of computed 5'-GGGG-3' and those of 
experimental 5’-GGG-3' was carried out (Figure 2.5). And the result shows that wherever 
the base is, the data between the corresponding bases is compatible. 
Moreover, it was found that there is more or less difference between the data 
calculated in solvent and that in gas phase. In most cases the data obtained in solvent is 
more close to the experimental value than that obtained in gas phase. Even though for the 
terminal base, the data is more "reasonable" in solvent. This result is inspiring. Not only 
does it implies an appropriate system (DNA model + counter ion + solvent) was chosen 
and a successful simulation was carried out, but also it primarily validates the high 
application of the hybrid M D + Q M method to the system. 
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Figure 2.5 Comparisons of Backbone Torsion Angles of Computed 5'-GGGG-3' and 
Experimental 5'-GGG-3' 
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Figure 2.6 Comparisons of Backbone Torsion Angles of Computed and Experimental 
5,-GGGG-3’ 
2.4.2 N7-N7 Distance 
As a reference, N7-N7 distance of two adjacent guanines was measured for the 
optimized structures GG, GGG, G G G G， G G G G G , G G G G G G , G G G G G G G , 
G G G G G G G G (Table 2.1). It's found that the average distance between the neighboring 
guanine varies from 3.91 A to 4.14 A, while the maximum distance is 4.7234 A and the 
minimum 3.5942 人.The data is also very close to the experimental value. According to 
Astbury (3), the inter base-pair distance of the first X-ray photographs of fibrous D N A is 
3.4 人.Fu suggested an average distance of 4.23 A from some X-ray and N M R sequences 
in her study (18). For the case of dodecamer d(CGCGAATTCGCG), the mean rise 
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distance is 3.33 人（9) and for B-form D N A generally, the stacked distance is 3.38 人. 
Although the calculated distance is more or less larger than the experimental one, in 
contrast with the data calculated in gas phase the average value of which varies from 4.95 
A to 6.35 A (Table 2.1), great progress was achieved. 
Table 2.1 N7-N7 Distance of the Optimized Structures of GG, GGG，GGGG, G G G G G , 
G G G G G G , G G G G G G G， G G G G G G G G 
GG" G G G G G G G Qs" G6 G7 G8 
01-02'4.0949(6.35/ 3.9329(5.54) 3.7035 4.3431 4.70404.1762 
G2-G3 - 4.0538(5.55) 3.9813(4.16) 4.7234 3.9046 3.7437 4.6653 
G3-G4 -- -- 3.7596(5.29) 3.8397 4.4587 4.0353 4.1182 
G4-G5 - - - 3.8208 3.7342 4.1477 3.9866 
G5-G6 - - - - 3.7994 4.3688 4.3271 
G6-G7 -- -- - -- - 3.5942 3.8310 
G7-G8 -- -- - - -- -- 3.8397 
Average" 4.0949(6.35) 3.9934(5.55) 3.9133(4.95) 4.0218 4.0480 4.0989 4.1349 
a The sequence direction is from 5' terminal to 3’ terminal 
b The value in bracket showing the results calculated in gas phase with pure quantum 
mechanics method 
c Base pair step, starting from the 5' terminal 
d Average value of G1-G2, G2-G3, G3-G4, G4-G5, G5-G6, G6-G7，G7-G8, if applicable 
e G5 represents 5 consecutive G, so and so forth 
Furthermore, the average distance doesn't become smaller as expected but 
disordered as the sequences become longer (Table 2.1). This result implies that the hybrid 
method doesn't depend on the length of the sequence. But for the calculation in gas phase 
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with pure quantum mechanics method, this is not the case (18). The N7-N7 distance 
becomes smaller as the D N A sequence becomes longer. Based on this, Fu proposed a 
scaling factor deducing from 2, 3 and 4 base pairs to predict the distance value of 
sequences with other lengths. She also concluded that D N A models with a minimum of 
six base pairs are necessary and models with twelve base pairs are the best representation 
of B-DNA. But during the molecular dynamics process, D N A models accompanying 
with the counter ions and the solvent molecules have enough time to relax. This 
"simulates" a more realistic situation and may be responsible for the disordered average 
N7-N7 distance. Also note that the D N A models calculated in gas phase was constructed 
using SYBYL 6.2 (18, 52)，but the models calculated in solvent was built using A M B E R 
9 (40). This may also have some influence but the effect may be not that vigorous. 
In summary, like the situation of backbone torsion angle, N7-N7 distance is more 
reasonable calculated in solvent with the hybrid M D + Q M method than in gas phase with 
pure quantum mechanics method. In addition, the data in solvent has no obvious 
correlation with the length of the D N A sequence, which is different from the situation in 
gas phase. For 2 to 8 consecutive guanine models, the fluctuating range of the average 
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distance is just 0.23 A. It implies no matter how long the D N A models are, the results 
always remain reasonable. 
2.4.3 Location of HOMO 
To further verify the applicability of the method, another comparison of locating 
the M O with RHF/ST0-3G method (18) in gas phase was carried out. Figure 2.8 lists the 
H O M O comparison results of AG, GA, G G and A A models. The H O M O s from the two 
methods match very well. Fu once had a comparison of her obtained H O M O s with the 
experimental results and found they are compatible (18). She also had a calculation using 
a higher level of theory, namely UB3PW91/6-31 lG(d, p)�and it was found that in spite 
of the difference in the shape of the H O M O s obtained by two computational methods, the 
major position of H O M O s is same. Since the H O M O results obtained by different 
methods are compatible, it once again indicates the hybrid M D + Q M approach is practical 
and appropriate for illumination for the systems. 
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Figure 2.7 Comparisons of Locations of H O M O of 2 Base-Pair Models Computed by 
Hybrid Method in Solvent and Pure Quantum Mechanics Method in Gas Phase 
* 3-2IG basis set for C, H，0，N，Na; 6-3IG* basis set for P 
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2.5 Summary 
In this chapter, a hybrid M D + Q M method was applied to the systems containing 
D N A models, counter ions and solvent molecules. This method is found to be really 
timesaving during the calculation. For an 8-mer D N A model, which is neutralized by 14 
Na+ and surrounded by about 2,000 water molecules, it costs only about 1.5 days for a 
120 ps molecular dynamics simulation and about 0.5 days for a quantum mechanics 
calculation (water molecules were tripped from the system for ab initio calculation). 
Besides, by comparing the computed (in solvent and in gas phase) and experimental data 
of the backbone torsion angles, the reference distances, as well as the locations of H O M O , 
it's found that the results obtained by the hybrid method approaches the experimental data 
more closely than those obtained by pure quantum mechanics method in gas phase. It is 
concluded that this method can at least semi-quantitatively calculate the electronic 
structures of D N A and it is thus adopted for the further study. 
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CHAPTER THREE 
UNDERSTANDING OF THE CISPLATIN-DNA CROSSLINKS 
3.1 Introduction 
N o w it's well established that the anti-tumor activity of cisplatin resulted from 
binding to D N A bases at the N7 position of the imidazole ring of guanine (G) or adenine 
(A) (23) and that binding is preferentially at G (27, 53). In the past few years, much 
research work focused on the subtle chemical process of the interaction between cisp latin 
and DNA, such as charge transfer (54, 55), hydrogen bonding pattern (42, 56，57), proton 
transfer (58), hole migration (59), 7i-stacking interactions (60) and so on. Less work, 
however, was carried out towards the interaction between cisplatin and whole D N A 
sequences. If the D N A sequence changes, the impact on its interaction with cisplatin is 
unknown. Fu did a precursory and meaningful job with respect to this in 2004 (18). In her 
research, a series of D N A models was calculated at the RHF/ST0-3G level and based on 
that a set of rules was raised up to predict the binding site where cisplatin would connect. 
Although her work is promising, the results suffer from the systematic disadvantage due 
to the computational method. In last chapter, a hybrid method, namely M D + Q M method, 
was demonstrated to be highly applicable to the D N A models. In this chapter, the hybrid 
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method was employed in determining (i) the potential binding products of cisplatin-DNA, 
and (ii) the structural investigation of the D N A models from a theoretical perspective. 
3.2 MO Analysis 
In the ligand chemistry theory, a ligand substitution reaction occurs due to the 
interaction between the Highest Occupied Molecular Orbital ( H O M O ) of the ligand and 
the Lowest Unoccupied Molecular Orbital (LUMO) of the substrate (61). In the case of 
cisplatin-DNA binding, it's thus expected that the electrons of H O M O (for 
monoflinctional), or with the electrons of HOMO-1, i.e. the next Highest Occupied 
Molecular Orbital (for bifunctional) of D N A donate to the L U M O of cisplatin. As stated 
in Chapter 2, generally the H O M O of D N A locates on guanine bases. To further validate 
this and investigate the impact of sequence effect on the M O location, in this study, the 
H O M O and H O M O - 1 of selected D N A sequences were located and a new rule was 
proposed to predict the binding product. 
i. 3 Potential Binding Products with the Ligand 
The possible binding products can be predicted from the location of H O M O and 
H O M O - 1 of D N A as stated above. Five kinds of crosslinks can be formed from the 
calculated results (Figure 3.1). 
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(a) l,2-d(GpG) Intrastrand Crosslink 
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Figure 3.1 The Location of HOMO and HOMO-1 of the Base-pair Models, and the 
possible Crosslink to Cisplatin 
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(a) 1,2-d(GpG) Intrastrand Crosslink (cont'd) 
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Figure 3.1 The Location of HOMO and HOMO-1 of the Base-pair Models, and the 
possible Crosslink to Cisplatin 
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Figure 3.1 The Location of HOMO and HOMO-1 of the Base-pair Models, and the 
possible Crosslink to Cisplatin 
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,2-d(GpG) Intrastrand Crosslink (cont'd) 
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(a) 1,2-d(GpG) Intrastrand Crosslink (cont'd) 
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(c) 1,3-d(GpXpG) Intrastrand Crosslink (cont'd) 
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Figure 3.1 The Location of HOMO and HOMO-1 of the Base-pair Models, and the 
possible Crosslink to Cisplatin 
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(d) d(GpC)d(GpC) Interstrand Crosslink (cont'd) 
H O M O HOMO-
n c
 G l ^ 
f G G
 e r r . 
• O c
 c
 G ^ y 
t G
 G
 e r r . 
Figure 3.1 The Location of H O M O and HOMO-1 of the Base-pair Models, and the 
possible Crosslink to Cisplatin 
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(e) d(GpXpC)d(GpXpC) Interstrand Crosslink (cont'd) 
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Figure 3.1 The Location of H O M O and H O M O - 1 of the Base-pair Models, and the 
possible Crosslink to Cisplatin 
3.3.1 1,2-d(GpG) Intrastrand Crosslink 
The H O M O s and HOMO-Is of the models GG, AGG, TGG, GGA, GGT, GGG, 
CGG, A G G A , G G G G , and T G G T were located on two adjacent Gs (Figure 3.1a). For 
some models like TGG, GGA, GGT, G G G and G G G G , H O M O and H O M O - 1 distributes 
over two G. However, the ultimate product remains the same. 
3.3.2 1,2-d(ApG) Intrastrand Crosslink 
The M O calculation results of the D N A models AG, AAG, A G A showed that the 
potential product with cisplatin was l,2-d(ApG) intrastrand crosslink (Figure 3.1b). Since 
there is only one G in the models, the H O M O (or the majority of it) just locates on that G. 
The HOMO-Is were found on adjacent 5'A of the H O M O - G . This agrees with the 
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experimental result that 1,2-d(ApG) crosslinks were usual while l,2-d(GpA) products 
were hard to find. For the case of A AG, both H O M O and H O M O - 1 distribute over two or 
even three bases, which reveals a fierce competition towards the electrons. However, it 
can be still concluded that the majority of the products can be determined as 1,2-d(ApG) 
rather than 1，2-d(ApA) from the figure. 
3.3.3 1,3-d(GpXpG) Intrastrand Crosslink • 
Only the model G A G was determined to be responsible for the l,3-d(GpXpG) 
intrastrand crosslink (Figure 3.1c). The H O M O - 1 distributes over A and 3'G and this may 
lead to two products, i.e. 1,2-d(GpA) and 1,3-d(GpXpG). Considering 1，2-d(GpA) is hard 
to form, l，3-d(GpXpG) was determined as the ultimate product. 
3.3.4 d(GpC)d(GpC) Interstrand Crosslink 
The models GC, GGC, C G G C gave the products as the d(GpC)d(GpC) interstrand 
crosslinks. No obvious electron distribution over bases was observed in these models, 
which implies high tendency to yield d(GpC)d(GpC) interstrand crosslink. 
3.3.5 d(GpXpC)d(GpXpC) Interstrand Crosslink 
Only the mode丨 C A G gave the product as d(GpXpC)d(GpXpC) interstrand 
crosslink. Electron distribution profile implies that the tendency to form the unique 
product is also very high. 
-44-
J = H O M O 
n = H 0 M 0 - 1 
N.A. = Not Available 
Figure 3.2 Summaries of the Locations of HOMO and HOMO-1 of DNA Models 
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3.3.6 Summary 
To have a wider and deeper understanding of the M O analysis, the locations of 
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3.4 Potential Binding Products Analysis 
A set of empirical "Selection Rules" was proposed by Fu (18) allowing the 
H O M O and the nearby active site to be located based on the calculated results. However, 
as stated in Chapter 2, the methods she adopted suffer from some disadvantages and thus 
the results obtained were not accurate enough. Here, based on the re-calculated results 
using the hybrid M D + Q M method, a new rule was proposed to predict the potential 
binding products o f D N A with the ligand. The active sites of some experimental Pt bound 
sequences, which are extracted from Protein Data Bank (PDB), were then predicted using 
the new rule and a comparison between the two results was carried out. 
3.4.1 Site Identification Convention 
To make the expression clear, a site identification convention for D N A was given. 
For a double helix d(X 2 X 丨 ZY, Y ^  )d(Y ^  'Y, 'Z'X, ’X ^ ')’ on the assumption that strand II 
is complementary to strand 1, the identification detail was shown in Figure 3.3. X, and 
Y, are the adjacent neighbours of Z; X^and Yjare the next adjacent neighbours of Z; 
X,' and Y,' are the nearest neighbours of Z; X 2' and Y 2' are the next nearest neighbours 
ofZ. 
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Adjacent to Z — ~ i Next adjacent to Z 
\ + 
I: 5�X2 Xi Z 丫1 丫2 -3' 
II: X2' XV Z Y^ ' Y2' -5' 
Next nearest to Z Nearest to Z — 
Figure 3.3 Site Identification Conventions 
3.4.2 Potential Binding Products Analysis 
According to the ligand substitution reaction theory, binding products were 
resulted from the interaction between the H O M O (and H O M O - 1 for bifiinctional 
products) of the ligand and the L U M O of the substrate. The M O analysis above also 
revealed that the binding of D N A with the ligand is not random but well-regulated. For 
example, for any sequence containing only one G，the H O M O simply always locates on 
that G. This is due to the lowest IP value of G among the four D N A bases (Table 1.1). 
For a sequence containing two or more Gs, the situation becomes complicated. In most 
cases especially in the case that a sequence containing adjacent purine bases, it just 
cannot specify the unique location where the H O M O locates due to the fierce competition 
towards electrons. The ultimate shape of H O M O looks more "diffuse" than that of those 
sequences containing only one G. But from another point of view, one of the two sites 
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which compete for the electrons is H O M O , or HOMO-1. So when prediction was to be 
made, it is more reasonable to use the two active sites together than separately to predict 
the ultimate products. In other words, the old selection rule which uses the H O M O and 
H O M O - 1 binding site separately to predict the binding products can be replaced by a new 
advanced rule which uses the two most active binding sites together to directly predict the 
binding products. The new rule was summarized in Table 3.1 as follows. 
Table 3.1 Procedures to Predict the Binding Products o f D N A with the Ligand 
I. H O M O locates at G for sequences containing only one G. The according potential 
product was mono functional’ or l，2-d(ApG). 
II. For sequences containing more than one G, H O M O also locates at G. And the 
potential product can be predicted by the following priority and step outlined. 
Step Details Potential 
Binding 
Products* 
1 If there exists such a G with adjacent G or A, or next adjacent G, or 
nearest G, or next nearest G in the sequences, remove those G(s) 





2 If n > 4, identify G without G or A as adjacent neighbor. If the 





3 If there exists GG in the strand, remove other G(s) only with adjacent 
A, or next adjacent, nearest, next nearest G or A. If there exist two or 
more GG, identify that with the most nearest G or A (see GG as a 
whole). If there are still two or more GG, remove that with the most 
next adjacent G or A (see GG as two individuals here, and thus there 
are 4 next adjacent bases in total). If the sequence contains GGC 
fragment, it's also very possible to form d(GpC)d(GpC) product. 
1,2-intra, 1,2-
inter 
4 1，3-intrastrand 1 ’ 3-intra 
5 1,2-interstrand 1，2-inter 
6 1,3-interstrand 1,3-inter 
7 l，2-d(ApG) 1,2-AG 
*n represents the number of G in the sequence 
#l’2-intra = l,2-d(GpG); 1,3-intra = 1,3-ci(GpXpG); 1,2-inter = d(GpC)d(GpC); 
1,3-inter = d(GpXpC)d(GpXpC); 1,2-AG = 1,2-d(ApG) 
For sequences containing more than one G, the first thing to do is to distinguish 
different kinds of G. If a G is totally isolated (i.e. without adjacent G or A, or next 
adjacent, nearest, next nearest G in the sequence) while other G(s) are not, it's more 
possible for the ligand to bind with other G(s) to form bifunctional product rather than 
binding with the isolated G to form monofianctional product. So step 1 is given. Then 
identify G without G or A as adjacent neighbor. The G(s) identified from this step has no 
adjacent G or A. This guarantees no fierce competition towards electrons with the G(s) 
and thus reasonable. The condition n > 4 makes sure that the D N A chain is long enough 
to make sense. Besides, G on the 5’ side is believed to be more reactive in general (15, 
16). So if the potential product is inter-strand, identify 5’ position G in the other strand. 
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The details in step 3 are a little complicated. This step deals with the situation that 
there is one or more G G fragment(s) in the sequence. Usually this kind of D N A models 
can easily form 1,2-d(GpG) crosslink product. So firstly those G(s) only with adjacent A, 
or next adjacent, nearest, next nearest G or A are removed. If there exist two or more GG, 
identify that with the most nearest G or A (see G G as a whole). This is because the 
nearest G or A can help to compete for electrons with its opposite base and thus make the 
competition between G G and its adjacent base (i.e. the opposite base to the nearest G or 
A) weaker. If there are still two or more G G left, remove that with the most next adjacent 
G or A since the next adjacent G or A would compete for electrons with G G fragment 
and make its IP value become larger and thus electron donation property weaker. In the 
sequences containing G G C fragment, the statistical result shows that there is also great 
possibility to form d(GpC)d(GpC) product. 
The following procedures are relatively simple. During step 4 1,3-intrastrand 
crosslink product is formed; then 1,2-interstrand crosslink product formed, step 5; and 
then 1,3-interstrand crosslink product formed, step 6; and at last l,2-d(ApG) crosslink 
product was given. These procedures also come from the statistical results and in most 
situations it is right. It seems reasonable. One apparent fact is that 1,3-intrastrand 
crosslink product and 1,2-interstrand crosslink product are easily formed than 1,3-
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interstrand crosslink product due to the structural factor. l,2-d(ApG) are lastly formed 
due to the thermodynamics factor that the IP value of A (8.24 eV) is higher than that of G 
(7.75 eV). The difference makes A not that "preferred" by the most active site. 
The new rule was then applied to predict the potential binding products of the 
D N A models GGG, C G G and GGC. They are the very three models the ultimate binding 
products of which are different from those calculated in gas phase.- According to step 3 in 
Table 3.1, G G G and C G G are determined to give a 1,2-intrastrand product while G G C 
1,2-intrastrand or 1,2-interstrand product. This is consistent with the calculated results 
where G G G and C G G form 1,2-intrastrand products and G G C forms 1,2-interstrand 
product. In gas phase, however, 1,3-intrastrand product was given by GGG, while 1,2-
interstrand product given by C G G and 1,3-interstrand product given by GGC. By 
comparing the results in water and in gas phase, it can be seen that the results in water are 
more reasonable. Take G G G as an example, it's more convinced to form a 1,2-intrastrand 
product than 1,3-intrastrancl. Actually for the sequence ATGGGT, the experimental result 
is indeed the 1,2-intrastrand product, not 1,3-intrastrand product (18). 
52 
3.4.3 Applications 
To further validate the new selection rule, sequences from the PDB and literature 
results which had been shown binding with cisplatin were chosen and compared. The 
results are listed in Table 3.2. 
Table 3.2 Comparison of the Predicted versus Experimental Binding Position of G G 
in the Formation of Cisplatin Binding Adducts 
No. PDB 
ID 
strand Sequence (5'-xxx-3') 






[ 1 ] 
CCTCGCTCTC 
^AGCGAGAG 






C C T C T � T C T C C 
GGAGACCAGAGG 
[ 1 ] 
C C T C T � T C T C C 
^AGACCAGA^ 
[ 3 ] [ 2 ] 





C C U C T � T C T C C 
GGAGACCAGAGG 
[ 1 ] 
CCUCTGGTCTCC 
� A G A C C A G A � 






C C T ^ T C C 
GGACCAGG 
[ 1 ] 
C C T ^ T C C 
� A C C A � 
[ 3 ] [ 2 ] 
C C T ^ T C C 
G G A ^ A G G 





[ 1 ] 
CCUCTCT^ACCTTCC 
G G A G A G A C C T ^ A A ^ 







strand Sequence (5 ' -xxx-3 ' ) 




C A T A G C T A T G 
G T A T C G A T A C 
C A T A G C T A T G 
G T A T C G A T A C 
C A T A G C T A T G 
G T A T C G A T A C 
7 I I IP 
(X-ray) I 
II 
C C T C G C T C T C 
G G A G C G A G A G 
[1] 
C C T C G C T C T C 
^ A G C G A G A G 
[2] 
C C T C G C T C T C 




C T C C ^ C C T 





C T C C G G C C T 






G G A G G C C T G A G G 
[1] 
C C T C A ^ C C T C C 
G G A G G C C T G A G G 







C C T C T C G T C T C C 
G G A G A C G A G A G G 
C C T C T C G T C T C C 






T A T G C A T A 
A T A C G T A T 
T A T G C A T A 
A T A C G T A T 
T A T G C A T A 




T A T匹 C A T 
A T A C C G T A 
[2 ] 
TAT 匹CAT 
A T A C C G T A 
[1 ] 
T A T些 C A T 
A T A C C G T A 
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(cont'd) 
PDB strand Sequence (5 ' -xxx-3 ' ) 





T A T � T A T 
ATACCATA 
TAT迎TAT 
A T A C C A T A 
TAT匹TAT 
















C T C T C ^ T C T C 
GAGAGCCAGAG 
C T C T C巡 T C T C 
GAGAGCCAGAG 














A T G G G T 
T A C C C A 
A T G ^ T 
T A C C C A 
A T G G G T 
T A C C C A 
Number with square bracket [ ] indicates the priority; indicates the results obtained in gas phase; 
2 indicates the results obtained in water; & indicates no PDB ID number but literature results (18). 
It's known from the table that the predicted binding sites using the new selection 
rule match the experimental results perfectly. As comparison, there is too much 
uncertainty for the predicted binding sites using the "old" selection rule (18). It indicates 
the new rule was more practicable and applicable for the realistic situation. The only 
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model which detains some uncertainty under the new rule is sequence No. 17. There is a 
G G G fragment in the sequence. Generally speaking, the new rule can't deal with three or 
more consecutive Gs situation. It's necessary to have an extra calculation towards pure G 
models and the results can be used specially to predict that situation. The binding results 
for 5-8 consecutive Gs are: GGG, G G G G . G G G G G , G G G G G G , G G G G G G G . 
G G G G G G G G . That three Gs were underlined at the same time in some models indicates 
the electrons of H O M O and H O M O - 1 diffuse over those three bases and hard to 
distinguish. Two different kinds of 1,2-intrastrand crosslink products may thus be formed. 
3.5 Cisplatin-DNA Crosslink Products A nalysis 
As an application of the calculated results, cisplatin as an important ligand 
binding with D N A was carefully examined structurally. 
The chemical structural formula of cisplatin (CDDP) was listed in Figure 1.10a. 
Cisplatin and cisplatin-H 2 O (CDDP-H 2 O) was ever optimized at the RHF/STO-3G and 
RB3LYP/LANL2DZ level of theory (18). Figure 3.4 illustrates the optimized structures 
of cisplatin (a) and cisplatin-Hj O (b) at RB3LYP/LANL2DZ level of theory. 
In theory five crosslink products can be formed (chapter 3.3.1-3.3.5). In 
experiments however, only four products had been identified. They are l,2-d(GpG), 1,2-
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d(ApG), l，3-d(GpXpG) intrastrand and d(GpC)d(GpC) interstrand crosslink adducts (62-
64). In order to further understand the interaction between cisplatin and DNA, the helical 
parameters of the optimized geometries and experimental sequences were analyzed with 
C U R V E S 4.1 (65-67). Analysis will be firstly focused on the inter base-pair parameters, 
namely shift (Dx), slide (Dy), rise (Dz), tilt (x), roll (p) and twist (Q) (Figure 1.8). Then 
the four experimental crosslink products will be discussed in details. The torsion angles 
of the sugar-phosphate backbone (a, P, y, 5，s and《）and the orientation of the base 
(X) (Figure 1.6), together with the sugar ring conformation of each structure were also 
adopted to facilitate the analysis (Appendix I). 
3.60 96.7 
(a) Cisplatin (b) Cisplatin-HiO 
Figure 3.4 Diagrams of Optimized (a) Cisplatin and (b) Cisplatin-HaO 
RB3LYP/LANL2DZ Level of Theory 
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Detailed results of the inter base-pair parameters for all optimized geometries are 
summarized in Table 3.3. Table 3.4 lists the average value from the computed base-pair 
structures for each base-pair step. 
Table 3.3 Inter Base Pair Parameters of the Optimized Geometries。 
Base Pair Step Shift Slide Rise Tilt Roll Twist 
(Dx) (Dy) ( D z ) ⑴ （p) (Q) 
(AX, TX') 
(GX, CX,) 
(AA，TT) A1/A2 0.02 0.00 3.22 0.13 0.28 33.17 
(AG,TC) A1/G2 0.06 -0.05 3.19 -0.86 1.24 32.67 
(GA，CT) G1/A2 0.02 -0.08 3.40 -0.75 1.53 37.20 
(GC，CG) G1/C2 0.03 -0.02 3.77 -1.43 1.06 34.75 
(GG,CC) G1/G2 0.00 -0.02 3.75 0.32 -0.02 32.08 






































-0.44 4.09 30.34 
-1.57 -2.08 32.99 
-4.07 2.44 37.29 





0.55 16.10 25.95 
-1.12 -2.83 38.95 
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[cont'd) 
Base Pair Step Shift Slide Rise Tilt Roll Twist 

















































































































-7.77 -2.47 35.88 
-3.49 5.31 28.49 
0.18 3.15 36.29 
-4.69 -3.04 30.30 
37.09 
30.13 
0.12 2.81 35.42 






Base Pair Step Shift Slide Rise Tilt Roll Twist 
(Dx) (Dy) (Dz) � (P) ( � 
(AGA,TCT) 
A1/G2 -0.06 -0.05 3.35 -1.32 7.13 35.93 
G2/A3 0.13 -0.11 3.60 -4.97 -3.60 35.80 
(XGGX, X'CCX’） 
(AGGAJCCT) 
A1/G2 -0.35 0.14 3.15 -1.61 -0.08 35.35 
G2/G3 0.05 -0.96 3.43 3.07 0.73 29.15 
G3/A4 0.40 0.43 3.05 0.67 2.14 37.08 
(CGGC,GCCG) 
C1/G2 -0.49 0.36 2.63 -3.48 4.96 33.93 
G2/G3 0.52 -0.39 3.18 -4.34 -0.08 28.32 
G3/C4 -0.22 -0.26 3.13 -1.74 0.39 29.31 
(GGGG，CCCC) 
G1/G2 0.16 -0.02 3.60 3.16 -1.78 32.46 
G2/G3 -0.40 -0.30 3.29 1.73 2.60 30.05 
G3/G4 0.29 0.21 2.69 1.10 3.65 29.83 
(TGGT，ACCA) 
T1/G2 0.26 -0.13 2.53 -2.10 17.91 25.32 
G2/G3 -0.53 0.27 3.93 -4.49 -7.88 39.96 
G3/T4 0.23 -0.51 3.41 0.29 1.28 31.31 
Distances (Dx, Dy, Dz) are given in angstroms, and angles (T,P,Q) are in degrees. 















A/A -0.18 0.05 3.13 -0.82 0.64 34.09 
A/G 0.12 -0.24 3.05 -1.84 2.34 31.40 
G/A 0.05 0.13 3.25 -0.75 0.72 37.03 
G/C 0.04 -0.19 3.41 0.87 -1.02 32.68 
[cont'd) 
Base-Pair Shift Slide Rise Tilt Roll Twist 
Step (Dx) (Dy) (Dz) (T) (P) 
G/T 0.05 0.40 3.21 0.35 -1.19 31.94 
G/G 0.00 -0.11 3.52 -0.25 -0.47 33.11 
C/G -0.37 0.20 2.76 1.66 5.87 33.93 
T/A -0.36 0.21 2.90 0.12 2.81 35.42 
T/G 0.43 -0.08 2.75 -0.01 12.27 29.81 
‘Distances (Dx, Dy, Dz) are given in angstroms，and angles (T,P,Q) are in degrees. 
3.5.1 1,2-d(GpG) and 1,2-d(ApG) Intrastrand Crosslinks 
For these two intrastrand products, the H O M O and H O M O - 1 locates on the 
adjacent purines. From Table 3.4 it's known that the average rises for step A G and G G are 
3.05，3.52, respectively. It's reported by Astbury (3) and Wilkins (68) that the stacked 
base-pair distance from the X-Ray data of D N A is 3.4 A. All the three data closely 
approaches the chloride to chloride distance, r(Cl-OH 2), of 3.19 A of the optimized 
cisplatin- H j O (Figure 3.4). Thus the binding to cisplatin is feasible. 
For l,2-d(ApG) and l,2-d(GpA) intrastrand crosslinks, both the M O results 
(Figure 3.2) and experiments (28) show that binding of cisplatin takes place on the A of 
the 5' side of d(ApGpA). The reason remains unclear (69). Considering that a larger rise 
and a larger twist angle for G A step (3.25, 37.03，respectively) than the value of A G step 
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(3.05, 31.40, respectively) (Table 3.4), it would be more difficult for ligation of G A to 
cisplatin. 
3.5.2 1, S-d(GpXpG) Intrastrand and d(GpXpC)d(GpXpC) Interstrand Crosslinks 
The M O results show that only G A G model forms l,3-d(GpXpG) intrastrand 
crosslink product and C A G d(GpXpC)d(GpXpC) interstrand crosslink product. The NT-
NT distances of these two models were measured and summarized (Table 3.5). Both the 
optimized and system-built distances are much longer than r(Cl-OH^) of 3.19 A. Even 
though a distance of 6.8 A [2 x 3.4A based on Astbury's (3) and Wilkins' (68)] was 
predicted for double stacked base-pairs, it remains much longer. Thus large structural 
distortion on D N A would happen if binding with cisplatin occurs (15, 16)，which renders 
these crosslinks structurally less favorable. 
Table 3.5 N7-N7 Distance ofG-G of the Optimized & System-Built G A G and C A G 
Model G A G C A G 
Optimized 7.96 10.31 
N7-N7 Distance /A 
A M B E R 8.18 9.44 
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3.5.3 d(GpC)d(GpC) Interstrand Crosslinks 
GC, GGC, C G G C models are showed to give the d(GpC)d(GpC) interstrand 
crosslinks according to the M O results. The N7-N7 distances of these three models were 
measured and summarized (Table 3.6). It's known from the table that the optimized NT-
NT distance is 8.69 A around. This value is larger than that of l，3-d(GpXpG) intrastrand 
crosslinks (7.96 A, Table 3.5) but smaller than that of d(GpXpC)d(GpXpC) interstrand 
crosslinks (10.31 A, Table 3.5). It indicates that it's relatively hard to form d(GpC)cl(GpC) 
products than 1,3-d(GpXpG) intrastrand crosslinks, but easier than d(GpXpC)d(GpXpC) 
interstrand crosslinks. The conclusion therefore validates parts of the new rule that 1,3-
intrastrand products firstly formed, then 1,2-interstrand and then 1,3-interstrand (Table 
3.1). 
It's also interesting to note that the three N7-N7 values of system-built GC, G G C 
and C G G C models are all equal to 7.77 A. Since C G G C has one more 5丨-C than G G C and 
G G C has one more 5,-G than GC, the observation may imply that when A M B E R 
software builds models, it just "adds" the base one by one without changing the 
conformation of the former structure. This hypothesis was proved by comparing other 
inter base-pair parameters of these three system-built models (Table 3.7). It was found 
that each parameter of the three models is almost equal from one another. 
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Table 3.6 N7-N7 Distance of the Optimized & System-Built GC, G G C and C G G C 
Model G C G G C C G G C 
Optimized 8.76 8.67 8.63 
N7-N7 Distance /A A M B E R 7.77 7.77 7.77 
Table 3.7 Inter Base Pair Parameters of the System-Built GC, G G C and G G G C 
Base Pair Step Shift Slide Rise Tilt Roll Twist 
(Dx) (Dy) (Dz) � (P) � 
G C G1/C2 0.00 0.00 3.39 0.00 0.00 36.00 
G G C G1/G2 0.00 0.00 3.38 0.02 -0.04 36.00 
G2/C3 0.00 0.00 3.39 -0.01 0.05 35.98 
C G G C C1/G2 0.00 0.00 3.37 0.01 -0.09 36.01 
G2/G3 0.00 0.00 3.38 0.03 0.00 35.98 
G3/C4 0.00 0.00 3.39 0.01 0.09 36.03 
“Distances (Dx, Dy，Dz) are given in angstroms, and angles (T，p，n) are in degrees. 
However, even the smallest value of N7-N7 distance in Table 3.6 is much larger 
than r(Cl-OH 2) of 3.19 A. So like the situation of d(GpXpG) intrastrand crosslink, large 
structural distortion on D N A would be induced if binding with cisplatin occurs, which 
also renders these crosslinks structurally less favorable. 
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3.5.4 Platination at Terminal Positions 
Generally cisplatin would not bind with terminal bases to form cisplatin-DNA 
adduct (Table 3.2) even if G G or A G fragment locates at terminal position. W e believe 
this is attributed to the terminal effect. The binding of cisplatin would become 
increasingly difficult due to the increase latitude of the "moving" nucleotides in the 
terminal position. This conclusion can be rationalized by comparing the backbone torsion 
angles among the results obtained from the calculation, N M R and X-ray trials. The 
experimental sequences were obtained from the Nucleic Acid Database (NDB) (49) 
where all sequences terminated with G G G were collected (Appendices I and II) (70). It's 
known that the angles of the terminal base deviate more or less from the experimental 
results, even N M R and X-ray data deviate from each other (Figure 2.2-2.5). However for 
the intermediary base this circumstance does not exist, confirming that the terminal base 
is dynamically unstable. 
3.6 Summary 
In this chapter, both the orbital and structures of the D N A models were re-
calculted using the hybrid M D + Q M method. According to the M O results, a new 
selection rule was proposed. Different from the "old" selection rule which locates the 
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H O M O and HOMO-1 in D N A separately, the new rule locates the two most active sites 
together to predict the potential binding products. The application of the new rule to the 
experimental sequences was extremely successful. Then cisplatin-DNA crosslink 
products were carefully examined from the structural point of view. The analysis not only 
further proved the correctness of the new rule, but also made the understanding towards 
the binding of cisplatin and D N A deeper. 
As a conclusion, the preference of binding is found to be sequence dependent, and 





The traditional hybrid Molecular Dynamics + Quantum Mechanics ( M D + Q M ) 
method was utilized to theoretically investigate the potential crosslink products of D N A 
with cisplatin. A series of short segment D N A models was selected. They are 5'-GX-3', 
51-AX-3•’ 5,-XGG-3,，5,-GGX-3’，5'-GXG-3', 5'-XAG-3', 5'-AXA-3'and 5'-XGGX-3' 
(where X = A, T, C and G). These models were firstly involved in a 120 ps M D 
simulation process, and then their geometries were averaged over the simulation time 
during which the Rmsd of the models has no wild fluctuation. Lastly M O analysis of their 
structures was undertaken at the RHF/GEN (6-3IG* for P atom, 3-2IG for other atoms) 
level of theory. 
Three parameters, namely backbone torsion angles, the reference distance as well 
as the H O M O location were compared between the data obtained from the hybrid method 
and the experimental data, or the results obtained from the reliable computational method. 
All of the results are highly compatible, and much better than the results obtained from 
the pure quantum mechanics method RHF/ST0-3G which has been proved to be a 
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qualitative method for the short segment D N A models, indicating that the utilized hybrid 
method was highly appropriate for the demonstration of the investigation. 
M O analysis was then carried out on all the D N A models, based on which a new 
selection rule was proposed. Different from the "old" selection rule which locates the 
H O M O and H O M O - 1 in D N A separately, the new rule locates the two most active sites 
together to predict the potential binding products. The application of the new rule to the 
experimental sequences was extremely successful. 
Then the four experimental crosslink products, namely l’2-d(ApG)，1,2-d(GpG) 
and l,3-d(GpXpG) intrastrand and d(GpC)d(GpC) interstrand crosslinks were carefiilly 
examined structurally. The results are in general agreement with experimental ones, 
although the different binding status, namely one bound, one not. 
The results also have some application on other anti-cancer drugs like 
intercalating-type drugs. These successful applications to the practical issues as well as 
the low computational cost consolidate the method utilized in this thesis to be a good 
choice when dealing with D N A and other biomacromolecule. 
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APPENDIX I 
BACKBONE TORSION ANGLES AND SUGAR RING CONFORMATIONS OF 
THE OPTIMIZED GEOMETRIES 
a p Y 8 e ^ X Conformation 



























-78.73 163.76 58.52 131.61 -143.94 -80.66 -138.36 C2'-endo 
I I 49.04 122.69 I I -97.39 Cl'-exo 
-75.10 173.65 50.13 129.57 -162.65 -83.89 -133.01 Cl'-exo 
I I 46.88 119.32 I I -111.52 Cl'-exo 
-73.62 171.28 58.47 1 32.23 -171.38 -88.65 -115.86 CZ-endo 
I I 52.07 121.29 I I -118.45 Cl'-exo 
-72.37 176.55 56.29 124.91 -167.11 -84.51 -136.01 Cl'-exo 
I I 51.50 124.91 I I -115.88 Cl'-exo 
-82.19 149.43 I 137.99 -78.85 137.93 -72.00 C2'-endo 
I I 39.94 139.62 I I -100.01 CZ-endo 
-69.41 170.02 58.00 117.15 -166.53 -86.52 -125.30 Cl'-exo 
I I 52.80 121.27 I I -106.89 Cl'-exo 
-69.82 1 76.85 57.06 119.31 -172.95 -87.16 -137.01 C1_ 
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(cont'd) 
a p Y 5 E 《 X Conformation 






54.72 121.45 •128.25 Cr-exo 
I I 51.98 126.81 I I -125.94 Cl'-exo 






1 2 c c
-69.23 179.74 57.32 123.62 -170.72 -88.79 -137.49 Cl'-exo 
I I 48.44 120.96 I I -129.26 Cl'-exo 
-71.08 174.82 58.18 124.70 -167.18 -83.51 -133.01 C1'-exo 






1 2 A c
-67.11 176.60 58.15 95.50 -162.13 -76.06 -159.82 C4'-exo 
I I 60.03 127.50 I I -127.71 Cl'-exo 
-70.75 173.71 57.55 129.16 -169.30 -84.72 -126.21 C2'-endo 











-64.31 174.60 59.06 84.93 -166.62 -75.08 -155.58 C3-endo 
-68.44 174.12 66.25 141.60-173.59 -88.29 -120.23 C2'-endo 
I I 50.74 114.68 I I -132.99 Cl'-exo 
-73.64-178.90 55.62 118.95 -164.33 -85.49 -143.98 Cl'-exo 
-70.17 170.29 49.70 118.14 -168.51 -86.48 -129.64 Cl'-exo 
I I 51.09 113.15 I I -121.10 cr-exo 
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(cont'd) 
a P y S E � X 







-73.98 -178.87 56.10 112.98-165.65 -98.75 -131.17 d'-exo 
-66.58 170.77 51.02 138.67-175.96 -91.00 -106.99 C2'-endo 





-73.79 171.34 62.58 109.22-159.71 -121.96 -116.85 C1’-exo 
-73.48 171.96 52.69 135.06-169.24 -88.02 -115.82 CZ-endo 
















49.80 118.99 I 
57.42 114.50 -170.84 
56.13 118.39-173.11 

























•75.87 170.01 59.51 123.86 _ 
-82.74 157.05 44.27 137.33 
I I 34.83 144.29 
-65.54 171.90 56.13 123.86 
-71.34 170.78 56.42 117.22 
I I 50.05 125.77 
•161.95 -80.60 -123.07 
-82.46 152.71 -92.46 
I I -109.44 
-174.52 -89.66 -120.00 
-169.15 -88.76 -118.10 







-65.91 173.64 56.43 119.78 -173.93 -91.49 -130.16 cr 
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(cont'd) 
a P y 5 e ^ X 
































-68.33 -178.84 53.93 107.36-171.67 -88.47 -129.94 
I I 50.96 120.33 I I -108.83 
-66.16 169.90 59.90 115.13-174.62 -91.07 -125.35 
-70.18 174.06 61.79 128.13-175.86 -94.02 -111.77 
I I 51.57 109.15 I I -131.97 
-64.90 -177.78 57.11 108.75 -171.01 -89.18-141.50 
-68.15 173.19 53.48 135.95-173.13 -90.65 -118.81 
I I 52.55 115.56 I I -127.45 
-72.06 175.19 58.64 112.86-161.98 -77.50 -153.00 
-66.65 174.74 56.25 124.31 -174.27 -89.20 -126.40 
I I 51.89 118.09 I I -128.72 
-79.08 165.49 58.22 129.28 -100.50 164.19 -93.07 
-67.51 171.92 41.68 142.11 -179.11 -94.52 -105.66 
I I 55.04 113.56 I I 
-62.84 172.96 58.01 117.14-174.70 -89.78 
-72.23 170.86 58.00 123.97-164.41 -86.73 






















-69.21 172.21 58.46 126.92-173.63 -89.90 
-65.63 171.15 49.50 93.68 -173.27 -83.55 









a P Y 5 e 4 X 































-75.62 173.28 59.88 101.93-162.87 -81.71 -135.97 
-67.79 162.65 56.44 135.83-152.46 -131.67 -99.92 
I I 52.73 126.84 I I -118.93 
-68.77 178.16 56.29 111.62-165.68 -85.16 
-68.48 172.48 56.35 127.87 -173.46 -91.60 
I I 50.75 132.82 I I 
-69.02-179.65 58.23 102.11 -164.63 -86.24 
-66.43 169.05 53.00 137.44-175.36 -91.38 







-93.41 158.07 59.65 127.41 -86.07 121.91 
-71.89 171.46 57.55 140.55-172.22 -88.67 
I I 49.31 123.19 I I 
-65.94 174.99 56.18 106.58-175.38 -90.44 
-69.25 170.51 54.51 108.41 -170.06 -84.66 







1 2 c T 
•68.18 1 75.53 59.66 98.98 -171.55 -91.30 -133.15 
-67.47 171.78 58.85 130.45-175.51 -86.70 -113.49 
I I 53.16 128.98 I I -112.36 
-66.55 175.02 58.05 106.07-171.78 -91.18 -138.04 























a p Y 6 8 ^ X Conformation 
P-05' 05'-C5' C5’-C4_ C4'-C3' C3'-03' 03'-P Cl'-N 




















( A A A j n ) 








-74.06-178.12 62.59 105.19-158.58 -83.05 -156.97 
-69.78 171.86 49.71 130.83-172.49 -90.48 -110.81 
I I 50.87 122.40 I I -113.08 
-66.97 175.39 56.96 119.66 -170.35 -87.19 -129.04 
-66.97 169.73 51.77 124.35-175.36 -89.06 -112.53 
I I 52.75 113.77 I I -118.42 
-74.24 178.23 55.46 112.93-164.57 -85.45 -135.21 
-70.96 172.89 48.86 128.25-173.86 -91.49 -110.01 
I I 50.17 117.31 I I -112.88 
-65.88 175.95 57.38 99.44 -171.04 -83.51 -146.38 
-70.62 173.77 58.82 124.44-169.25 -85.10 -122.12 
I I 49.78 129.88 I I -107.99 
-70.84 174.29 59.24 83.72-165.28 -73.14 -149.64 
-66.33 176.50 56.78 85.13-164.92 -70.52 -145.23 
I I 62.22 124.02 I I -123.09 
-69.21 171.89 58.07 121.84-169.22 -87.03 -134.89 
-68.06 170.76 55.14 117.39-175.32 -91.05 -119.24 





















a P Y 5 E 《 X 









-64.58 177.60 55.13 86.11 -159.11 -75.15-160.16 C3'-endo 
-71.39 176.56 62.77 142.91 -171.71 -86.85 -123.60 C2'-endo 
I I 48.78 115.51 I I -126.03 d'-exo 
-67.01 174.08 56.29 122.27-173.35 -91.23 -130.08 Cl'-exo 
-65.29 1 73.79 54.34 1 21.17-174.15 -87.86 -123.93 Cl'-exo 














-68.35 174.30-173.13 137.22 -166.62-113.80-110.76 
-68.94 171.56 52.15 136.82 -175.37 -90.73 -110.36 
-68.81 174.72 54.34 107.89 -166.83 -88.20 -129.36 
I I 51.64 134.44 I I -102.93 
I I I I I -128.16-116.59 
-69.65 169.65 I 135.27-173.56 -92.10 -108.71 
-66.82 171.05 54.61 104.22 -174.49 -88.94 -131.70 









C1 -77.51 179.38 58.83 112.52 -162.86 -89.96 -135.04 cr-exo 
G2 -65.54 168.66 50.45 130.46 -177.40 -90.43 -104.64 C2'-endo 
G3 -66.68 168.94 53.56 108.36-•170.69 • 96.53 -123.52 cr-exo 
C4 / / 54.48 120.85 / 1 -120.53 cr-exo 
5'GCCG 
G1 -65.77 169.76 58.10 117.02 -176.60 -91.62 -120.38 cr-exo 
C2 -65.65 171.37 56.24 99.60 -175.42 -90.43 -134.15 01'-endo 
C3 -72.08 171.75 60.26 114.90 -166.22 -82.79 -125.63 cr-exo 
75 
(cont'd) 
a p Y 5 E ^ X Conformation 
P-05' 05'-C5' C5'-C4" C4'-C3' C3'-03' 03'-P Cl'-N 
G4 / 1 50.65 127.39 / 1 -106.72 Cr-exo 
(GGGG,CCCC) 
5'GGGG 
G1 -65.87 173.70 56.96 124.95-172.52 • 88.43 • 133.17 Cr-exo 
G2 -72.55 178.66 52.06 120.87-170.96 • 92.04 • -129.91 cr-exo 
G3 -72.41 173.11 49.76 116.53-168.72 • 84.11 . •130.72 C:i_-exo 
G4 1 1 49.30 116.97 1 1 • 119.70 C:i_-exo 
5'CCCC 
C1 -66.82 174.64 58.57 101.08--172.43 -86.65 -135.83 Or-endo 
C2 -66.88 170.65 54.84 125.90 • -174.35 -89.82 -118.00 cr-exo 
C3 -70.68 179.56 55.51 112.96 -172.15 -91.19 -133.74 cr-exo 
C4 1 / 50.49 118.16 / / -133.14 cr-exo 
(TGGT,ACCA) 
5TGGT 
T1 -71.30 169.44 61.56 109.09 -167.50 -85.34 -114.67 cr-exo 
G2 -79.11 148.08 48.61 140.05 -84.73 147.91 -91.82 C2'-endo 
G3 -68.92 173.93 43.04 138.92 -174.31 -92.39 -118.79 C2'-endo 
T4 / 1 54.15 119.21 / / -122.08 cr-exo 
5'ACCA 
A1 -65.33 170.72 58.50 125.70-176.98 -98.99 1 -106.99 cr-exo 
C2 -63.07 172.67 55.99 115.67 -175.98 -91.23 -125.77 cr-exo 
C3 -80.46 173.61 59.62 125.36 -162.65 -85.53 -122.83 C1'-exo 
A4 1 1 45.89 130.04 1 1 -94.48 cr-exo 
76 
APPENDIX II 
BACKBONE TORSION ANGLES OF THE EXPERIMENTAL SEQUENCES 




overall -109.40 183.32 116.26 135.10 196.49 -114.87 -117.33 
(250.60) (183.32) (116.26) (135.10) (196.49) (245.13) (242.67) 
NMR -69.36 172.04 65.62 129.91 172.21 -102.78 -110.69 
(290.64) (172.04) (65.62) (129.91) (172.21) (257.22) (249.31) 
X-Ray -114.98 184.81 123.42 135.83 199.92 -116.58 •118.26 
(245.02) (184.81) (123.42) (135.83) (199.92) (243.42) (241.74) 
Average value with terminated GGG only 
overall n.a. n.a. 238.28 138.38 187.01 -103.81 -118.61 
n.a. n.a. (238.28) (138.38) (187.01) (256.19) (241.39) 
NMR n.a. n.a. 88.05 127.25 143.82 -65.50 -116.02 
n.a. n.a. (88.05) (127.25) (143.82) (294.50) (243.98) 
X-Ray n.a. n.a. 239.82 124.67 195.26 -108.30 -120.78 
n.a. n.a. (239.82) (124.67) (195.26) (251.70) (239.22) 
Average value with GGGG sequence 
overall -149.57 192.18 170.53 134.56 192.41 -106.92 -121.35 
(210.43) (192.18) (170.53) (134.56) (192.41) (253.08) (238.65) 
NMR -57.06 161.13 64.10 136.80 184.65 -103.54 -124.12 
(302.94) (161.13) (64.10) (136.80) (184.65) (256.46) (235.88) 
X-Ray -158.52 195.19 178.51 134.39 192.99 -107.18 -121.14 
(201.48) (195.19) (178.51) (134.39) (192.99) (252.83) (238.86) 
Standard deviation 
overall 94.82 34.91 102.86 19.60 35.83 46.91 34.78 
NMR 16.39 15.85 34.07 14.42 25.34 33.61 20.35 




Standard deviation with terminated GGG only 
overall n.a. n.a. 107.48 14.61 33.65 38.45 21.43 
NMR n.a. n.a. 80.56 19.68 49.30 37.44 28.15 
X-Ray n.a. n.a. 87.39 13.23 24.33 35.20 21.07 
Standard deviation with GGGG sequence 
overall 120.74 43.50 123.31 24.06 33.25 46.35 23.22 
NMR 3.70 3.10 1.58 13.46 5.40 15.87 4.79 
X-Ray 122.87 44.45 124.25 24.78 34.41 47.95 24.06 
NMR 
169D n.a. n.a. 180.63 108.04 178.35 -87.69 -130.51 
1G5K -65.86 192.16 64.59 143.60 173.80 -100.21 -122.14 
1GJ1 -73.96 182.02 55.03 132.60 183.63 -118.70 -103.11 
1IV6 -57.20 165.31 60.18 141.76 185.09 -97.26 -128.20 
-79.09 174.49 53.80 111.01 183.18 -96.98 -118.04 
1J5N -45.71 143.08 56.09 113.65 169.24 -97.84 -111.86 
n.a. n.a. 49.62 126.36 87.36 -22.26 -83.58 
1KBD -59.46 159.36 62.38 143.94 189.97 -109.98 -124.00 
1KVH -83.33 198.38 60.88 110.99 170.85 -98.63 -89.47 
1LFU n.a. n.a. 33.90 147.36 165.76 -86.54 -133.98 
1LWA -52.80 164.72 64.45 121.28 179.19 -85.46 -128.97 
1N0K -96.75 175.74 56.58 135.75 179.17 -165.65 -75.47 
1NOO -89.92 177.83 55.05 137.20 180.53 -156.49 -80.94 
2KBD -58.90 159.32 65.47 145.19 184.78 -115.19 -119.40 
X-Ray 
PD0005 -59.21 238.19 27.59 150.67 181.60 -129.13 -95.31 
-233.71 162.85 176.82 147.11 196.57 -113.11 -140.19 
PD0010 -58.18 167.90 55.93 147.17 212.40 -138.27 -92.16 
n.a. 197.13 59.67 144.09 199.05 -145.72 -85.85 
PD0023 -119.81 213.69 71.95 108.57 153.60 -71.94 -117.33 
-159.89 244.85 105.47 91.18 168.11 •77,85 -120.92 
PD0024 n.a. n.a. 194.55 147.14 240.69 -171.67 -97.31 




PD0030 门.a. n.a. 293.41 147.13 162.08 -149.03 -156.29 
PD0032 -98.54 140.08 184.20 85.10 215.95 -81.57 -179.57 
PD0033 n.a. n.a. 3.79 152.19 163.01 -148.11 -165.20 
PD0041 -90.26 179.66 58.81 147.81 209.76 -152.63 -58.40 
PD0068 -163.05 229.09 63.44 149.38 222.40 -126.08 -106.06 
PD0095 -279.17 190.08 181.67 147.04 189.12 -119.38 -118.60 
-271.38 193.84 176.70 146.40 189.25 -121.33 -121.38 
PD0105 -329.64 209.08 279.95 153.36 170.98 -89.64 -124.66 
PD0112 n.a. n.a. 326.77 148.48 184.81 -88.14 -125.20 
-2.87 267.42 264.78 154.76 186.60 -74.50 -133.15 
n.a. n.a. 338.76 148.67 182.98 -93.06 -123.28 
-349.02 268.51 271.14 149.82 184.64 -80.08 -135.72 
n.a. n.a. 333.61 145.57 186.79 -90.59 -126.29 
-71.39 192.66 36.63 137.85 185.83 -101.37 -109.85 
n.a. n.a. 332.10 147.48 188.58 -92.91 -121.84 
-355.43 262.67 269.96 150.18 183.09 -76.50 -130.67 
n.a. n.a. 333.67 145.65 185.08 -88.57 -124.44 
-348.03 257.87 274.41 148.74 183.72 -78.08 -134.01 
PD0145 -21.05 180.83 359.81 160.08 194.30 -110.39 -105.54 
-289.55 107.86 325.64 152.89 174.72 -127.30 -71.63 
PD0146 -348.31 195.24 305.43 165.31 189.93 -93.39 -111.10 
-334.21 189.44 303.02 160.56 156.30 -72.81 -106.05 
PD0155 -62.86 179.63 51.52 139.75 202.80 -137.78 -290.63 
-67.78 175.36 60.32 134.27 205.52 -127.00 -298.32 
PD0165 -50.19 148.03 45.44 125.26 189.06 -113.96 -130.11 
-57.05 141.48 38.97 118.09 191.90 -113.74 -133.31 
-57.67 134.92 39.57 119.17 192.73 -115.13 -132.76 
-59.78 140.68 50.41 124.65 191.45 -117.16 -134.53 
-71.19 178.05 50.42 143.57 194.06 -151.05 -102.96 
-43.32 142.28 38.10 130.65 182.26 -106.93 -127.33 
PD0192 -42.76 169.90 50.93 146.42 209.31 -102.08 -96.92 
PD0200 -60.16 175.44 34.79 153.57 237.41 -178.97 -65.51 
PD0219 -69.63 174.23 33.05 142.83 226.71 -145.18 -90.27 
-74.25 176.40 35.99 143.23 243.41 -172.24 -90.89 




-72.47 175.66 35.58 141.27 226.02 -144.69 -91.01 
PD0221 -205.05 218.81 164.15 136.69 244.87 -163.59 -112.24 
PD0222 门.a. n.a. 298.95 150.49 236.57 -76.71 -81.76 
PD0230 -43.14 142.11 41.06 133.80 181.37 -104.09 -127.16 
PD0231 -46.01 141.56 44.34 133.48 181.78 -102.92 -123.08 
PD0251 -59,86 151.23 36.17 145.60 195.28 -94.67 -115.89 
PD0252 -262.97 216.93 190.27 143.56 208.24 -74.46 -143.89 
PD0259 -78.46 174.03 44.85 150.85 309.17 107.94 -78.00 
-56.49 163.15 48.83 139.85 193.71 -139.56 -95.70 
PD0270 -282.06 226.18 179.06 101.39 221:64 -96.27 -171.48 
PD0286 -51.70 179.30 41.37 136.15 272.40 -211.83 -84.49 
-64.37 201.33 29.31 139.27 235.00 -167.25 -89.56 
-56.03 174.06 50.12 138.74 170.62 -121.66 -106.23 
-29.78 179.73 52.36 142.56 181.53 -103.89 -101.74 
PD0307 -209.67 190.89 179.60 137.91 224.96 -83.84 -154.07 
61.94 204.88 172.70 89.81 170.72 -48.88 -139.50 
PD0309 -96.61 214.70 50.03 137.46 136.39 -75.84 -79.96 
-76.35 154.43 56.40 145.03 204.24 -104.30 -78.57 
PD0310 -69.93 183.56 30.65 139.32 284.16 -201.38 -98.71 
PD0312 -51.21 142.90 42.02 130.47 182.42 -106.37 -133.92 
-50.57 143.22 47.97 137.52 177.10 -99.41 -116.38 
PD0316 -67.08 170.57 53.70 147.63 239.81 -190.08 - 1 1 6 . 6 1 
-230.77 150.61 170.79 146.49 184.32 -106.24 -135.85 
PD0319 -62.42 191.26 48.06 148.66 170.84 -124.58 -76.03 
PD0320 -49.71 187.77 38.62 145.82 151.30 -101.30 -84.67 
PD0338 -92.99 192.35 55.73 161.69 319.34 -236.91 -77.07 
PD0364 -54.53 184.63 43.16 142.35 182.98 -135.16 -93.02 
PD0365 -59.16 184.13 47.88 142.80 193.79 -137.48 -88.97 
PD0393 n.a. n.a. 333.27 108.44 175.84 -55.59 -133.48 
-103.60 174.13 84.89 109.08 196.13 -96.70 -125.26 
-62.53 178.98 43.68 117.68 58.26 -308.11 -98.70 
-167.94 206.79 60.20 151.50 314.87 -217.40 -84.67 
-81.88 147.64 13.14 123.72 156.71 -90.34 -100.82 
PD0424 -58.75 147.27 39.98 141.38 204.99 -115.61 -131.97 




PD0429 -8.69 293.87 255.56 145.77 171.86 -85.70 -121.14 
-76.30 208.90 48.20 140.95 163.33 -86.02 -92.97 
-295.22 266.90 201.65 141.49 226.65 -153.99 -124.21 
-42.11 138.18 45.46 137.73 179.17 -126.59 -106.63 
PD0504 n.a. n.a. 289.55 136.23 191.56 -96.56 -106.42 
-52.70 172.01 35.42 139.54 225.51 -178.82 -94.27 
-50.27 141.45 43.44 138.87 191.73 -93.26 -113.56 
PD0505 n.a. n.a. 281.74 127.08 200.77 -98.29 -113.26 
-56.19 163.35 45.42 140.02 231.74 -177.30 -94.09 
n.a. n.a. 280.16 135.92 194:23 -91.44 -118.25 
-64.54 172.88 46.97 143.12 231.25 -171.17 -100.40 
PDE003 n.a. n.a. 220.27 113.25 192.07 -122.19 -109.36 
n.a. n.a. 214.75 147.53 196.01 -137.40 -105.12 
PDE011 n.a. 220.21 105.61 125.36 195.88 -84.19 -119.98 
PDE012 n.a. 214.59 69.57 145.30 219.99 -107.85 -110.70 
n.a. 244.04 37.48 163.60 171.43 -89.94 -92.06 
PDE0128 -145.06 189.81 73.06 82.01 207.23 -70.05 -172.87 
-79.51 181.57 49.90 90.56 210.60 -66.96 -162.61 
-78.19 169.78 57.67 73.49 196.67 -64.32 -172.92 
-92.86 182.51 71.48 76.53 219.43 -93.26 -176.20 
-300.37 158.36 55.71 67.74 204.36 -61.52 -168.17 
⑵ 
• 
a A Y 5 A X 
Average value 
overall -90.62 -177.62 68.37 130.53 191.46 -106.80 -116.98 
(269.38) (182.38) (68.37) (130.53) (191.46) (253.20) (243.02) 
NMR -90.09 -166.41 76.60 133.50 185.17 -107.94 -118.12 




X-Ray -90.68 -179.09 67.29 130.14 192.29 -106.66 -116.83 
(269.32) (180.91) (67.29) (130.14) (192.29) (253.34) (243.17) 
Average value with terminated GGG only 
overall -68.00 -191.93 51.30 128.49 195.60 -106.31 -116.01 
(292.00) (168.07) (51.30) (128.49) (195.60) (253.69) (243.99) 
NMR -80.45 -172.24 57.71 130.46 179.64 -104.55 -118.55 
(279.55) (187.76) (57.71) (130.46) (179.64) (255.45) (241.45) 
X-Ray -73.18 -192.63 53.72 127.75 201.77 -108.10 -118.02 
(286.83) (167.37) (53.72) (127.75) (201.77) (251.90) (241.98) 
Average value with GGGG sequence 
overall -79.92 -174.03 53.06 128.78 194.66 -108.78 -117.43 
(280.08) (185.97) (53.06) (128.78) (194.66) (251.22) (242.57) 
NMR -74.92 -175.51 61.26 135.55 182.47 -104.93 -121.16 
(285.08) (184.49) (61.26) (135.55) (182.47) (255.07) (238.84) 
X-Ray -80.29 -173.92 52.45 128.27 195.57 -109.06 -117.14 
(279.71) (186.08) (52.45) (128.27) (195.57) (250.94) (242.86) 
Standard deviation 
overall 71.54 56.86 61.21 22.89 31.45 43.09 26.20 
NMR 61.08 31.36 44.12 9.90 16.84 18.90 13.44 
X-Ray 73.08 59.35 63.21 24.08 32.86 45.38 27.49 
Standard deviation with terminated GGG only 
overall 25.29 31.29 27.19 18.35 20.92 35.35 17.90 
NMR 20.78 16.65 2.70 9.92 7.21 13.50 8.93 
X-Ray 25.94 32.34 29.60 19.75 21.40 38.40 19.29 
Standard deviation with GGGG sequence 
overall 48.33 59.41 47.21 22.90 44.55 56.91 30.93 
NMR 25.43 20.18 6.82 11.96 8.80 13.80 11.56 





169D -73.01 -182.22 57.83 128.27 179.81 -111.45 -122.86 
1G5K -80.26 -162.15 57.93 142.10 187.14 -105.28 -124.73 
1GJ1 -60.54 -186.84 66.36 138.31 167.14 -92.50 -93.81 
1IV6 -67.39 -185.30 59.04 129.96 182.79 -109.75 -124.14 
-65.30 -193.63 61.39 118.43 180.81 -93.71 -126.49 
1J5N -24.38 -182.88 28.10 120.98 173.20 -90.06 -112.02 
1KBD -64.41 -181.49 54.95 141.29 186.75 -113.22 •124.51 
1KVH -67.27 -177.39 61.89 123.91 190.91 -86.43 -97.96 
1LFU -64.78 -162.64 73.51 146.72 162:26 -111.50 -103.67 
1LWA -103.93 -153.02 60.34 121.81 172.35 -88.99 -108.29 
1N0K -233.07 -112.18 178.42 141.51 218.93 -148.13 -132.33 
1NOO -210.38 -91.52 167.52 138.64 216.85 -139.62 -134.04 
2KBD -56.43 -192.02 68.49 143.56 188.30 -112.56 -130.68 
a^y 
PD0005 -252.28 -118.45 174.09 152.00 182.40 -54.16 -155.37 
-326.08 -232.57 318.49 151.32 215.00 -137.26 -108.36 
PD0010 -54.49 -218.33 53.45 116.66 180.49 -88.92 -114.99 
-36.60 -218.04 47.78 137.60 196.10 -118.11 -106.29 
PD0023 -103.92 -161.16 75.61 111.30 185.71 -75.29 -128.80 
-77.07 175.15 67.20 92.76 163.13 -37.78 -137.99 
PD0024 -72.75 -210.92 46.49 139.87 183.03 -96.46 -116.03 
-75.18 -207.90 45.26 140.84 190.02 -101.16 -117.31 
PD0030 -84.30 -185.68 55.67 84.21 196.57 -57.84 •159.22 
PD0032 -75.04 -186.62 60.80 85.85 196.76 -57.05 -162.29 
PD0033 -76.67 -191.82 50.37 82.22 187.34 -43.50 -156.52 
PD0041 -60.21 -223.94 62.17 149.08 181.72 -121.94 -98.77 
PD0068 -61.16 162.62 29.99 145.04 272.59 85.87 -244.42 
PD0095 -51.30 -170.80 42.19 135.22 273.42 -157.47 -94.42 
-58.15 -168.84 43.54 130.43 271.49 -159.16 -93.47 
PD0105 -68.90 -145.06 40.00 154.15 182.73 -116.08 -99.20 
PD0112 -73.79 -165.79 42.20 130.86 188.16 -92.88 -114.06 
-81.72 -166.10 43.70 137.11 191.87 -109.70 -111.60 
-62.16 -168.48 35.67 132.85 185.07 -94.57 -111.70 
83 
(cont'd) 
-85.07 -156.28 44.03 139.57 184.18 -102.26 -104.99 
-63.92 -170.10 38.29 130.61 191.63 -94.42 -116.04 
-71.39 -167.34 36.63 137.85 185.83 -101.37 -109.85 
-60.91 -174.20 36.27 130.34 185.76 -92.04 -111.71 
-80.83 -159.41 41.82 135.83 182.23 -99.06 -106.79 
-68.41 -167.86 41.00 134.38 190.37 -98.39 -113.15 
-82.70 -159.71 44.53 141.69 189.57 -108.02 -109.75 
PD0145 -45.45 -158.16 -1.11 139.20 113.44 -57.36 -102.32 
-209.42 -307.94 133.59 176.93 251.65 -108.64 -102.32 
PD0146 -35.11 -153.06 -16.71 138.48 119.95 -56.75 -107.42 
-104.48 -146.37 53.18 101.02 114.59 -57.80 -113.99 
PD0155 -63.05 -195.87 56.39 143.72 179.64 -93.65 -107.78 
-67.69 -190.98 55.68 147.72 182.06 -100.63 -101.84 
PD0165 -60.28 -176.04 54.29 142.58 178.36 -85.21 -105.01 
-54.86 -191.77 60.12 143.72 197.50 -114.37 -117.92 
-51.78 -185.05 52.73 142.53 183.57 -89.60 -108.34 
-59.51 -188.76 60.28 139.64 176.56 -81.53 -123.21 
-53.49 -210.91 62.92 140.85 182.48 -86.41 -130.13 
-61.79 -162.33 48.66 142.38 172.04 -83.48 -107.12 
PD0192 -55.05 -202.57 36.43 142.11 252.27 -203.46 -75.80 
PD0200 -67.26 -222.07 49.35 147.54 210.76 -150.80 -89.90 
PD0219 -85.69 -228.59 63.74 70.74 189.90 -69.03 -160.44 
-307.19 -134.07 202.46 85.29 213.82 -66.69 -169.92 
-307.39 -132.27 203.94 85.32 214.06 -65.68 -168.69 
-82.20 -229.00 61.26 71.69 185.43 -65.82 -161.92 
PD0221 -44.60 -227.42 31.66 136.01 171.11 -106.62 -92.35 
PD0222 -109.33 -296.39 148.21 150.57 242.20 -118.16 -122.57 
PD0230 -58.62 -172.54 49.76 144.23 198.03 -123.48 -120.73 
PD0231 -58.53 -171.07 45.54 141.59 175.62 -95.56 -115.22 
PD0251 -74.61 -189.36 52.63 135.95 195.79 -135.47 -103.68 
PD0252 -72.72 -187.24 45.04 140.14 210.22 -149.12 -97.96 
PD0259 -180.32 -140.64 75.60 131.03 195.80 -122.88 -112.59 
-41.38 -200.70 35.87 134.98 202.42 -120.16 -113.60 
PD0270 -29.21 -197.90 44.06 135.11 187.45 -95.12 -131.05 




-49.60 -230.05 42.05 140.85 180.29 -143.83 -97.87 
-55.52 -178.91 49.64 145.30 193.82 -158.78 -84.25 
-42.39 -181.46 47.88 142.21 177.26 -78.03 -115.06 
PD0307 -68.48 -196.88 37.84 140.71 250.38 -190.95 -88.57 
-86.05 -171.24 52.15 80.46 144.98 -86.68 -134.41 
PD0309 -56.02 -141.61 39.09 148.61 200.84 -181.24 -95.29 
-89.33 -197.77 56.81 141.38 185.04 -140.46 -80.93 
PD0310 -297.32 -133.72 196.00 141.33 219.41 -135.50 -131.15 
PD0312 -46.85 -176.07 39.60 140.74 181.58 -106.36 -122.53 
-72.63 -164.43 52.42 141.39 199.44 -104.88 -106.71 
PD0316 -264.06 -105.71 177.90 135.65 207.48 -88.60 -151.97 
-316.93 -220.40 312.08 147.67 180.72 -113.40 -105.18 
PD0319 -52.79 -185.01 56.44 149.79 162.29 -93.04 -99.58 
PD0320 -46.11 -164.63 52.29 155.89 190.51 -128.36 -90.46 
PD0338 -149.91 -165.56 57.01 143.88 203.85 -121.76 -103.35 
PD0364 -41.66 -193.31 40.91 144.14 188.94 -138.57 -104.52 
PD0365 -41.02 -198.22 39.29 141.88 179.72 -145.38 -90.29 
PD0393 -103.60 -185.87 84.89 109.08 196.13 -96.70 -125.26 
-62.53 -181.02 43.68 117.68 58.26 -308.11 -98.70 
-167.94 -153.21 60.20 151.50 314.87 -217.40 -84.67 
-81.88 -212.36 13.14 123.72 156.71 -90.34 -100.82 
-84.44 -164.96 65.94 107.13 160.95 -56.78 -123.53 
PD0424 -55.91 -186.04 41.91 140.44 190.81 -116.46 -130.09 
-318.41 -192.66 315.33 170.93 187.40 -100.84 -124.34 
PD0429 -76.30 -151.10 48.20 140.95 163.33 -86.02 -92.97 
-49.57 -167.74 40.44 137.75 189.12 -118.21 -100.50 
-42.11 -221.82 45.46 137.73 179.17 -126.59 -106.63 
-319.53 -209.10 321.03 151.35 189.73 -77.35 -91.35 
PD0504 -52.70 -187.99 35.42 139.54 225.51 -178.82 -94.27 
-62.05 -179.90 36.44 140.66 199.53 -139.78 -93.56 
-40.42 -211.16 38.00 138.35 206.92 -164.87 -107.15 
PD0505 -56.19 -196.65 45.42 140.02 231.74 -177.30 -94.09 
-55.67 -214.24 39.85 137.59 199.79 -98.62 -113.07 
-64.54 -187.12 46.97 143.12 231.25 -171.17 •100.40 
-67.68 -211.86 49.62 139.65 186.90 -91.02 -117.14 
85 
PDE003 -23.87 -201.98 21.80 136.18 181.93 -100.91 -92.64 
-2.24 -231.14 27.60 125.24 170.80 -91.91 -103.53 
PDE011 -84.99 -184.10 51.23 119.27 164.51 -94.36 -101.99 
PDE012 -69.61 -229.23 79.04 75.49 195.32 -74.14 -153.71 
-94.64 -142.32 37.16 141.64 161.94 -102.30 -78.09 
PDE0128 -79.51 -178.43 49.90 90.56 210.60 -66.96 -162.61 
-78.19 -190.22 57.67 73.49 196.67 -64.32 -172.92 
-92.86 -177.49 71.48 76.53 219.43 -93.26 -176.20 
-59.63 -201.64 55.71 67.74 204.36 -61.52 -168.17 
-70.99 -198.60 61.98 73.15 204.04 -88.80 -177.18 
⑶ _ C o 
a 
Average value 
overall -85.98 -185.20 62.97 129.59 191.31 -113.09 -116.29 
(274.02) (174.80) (62.97) (129.59) (191.31) (246.91) (243.71) 
NMR -74.42 -187.14 58.03 130.12 162.66 -125.86 -118.40 
(285.58) (172.86) (58.03) (130.12) (162.66) (234.14) (241.60) 
X-Ray -87.50 -184.94 63.62 129.52 193.50 -112.11 -116.01 
(272.50) (175.06) (63.62) (129.52) (193.50) (247.89) (243.99) 
Average value with GGGG sequence 
overall -87.60 -185.87 64.25 126.73 191.55 -111.98 -117.34 
(272.40) (174.13) (64.25) (126.73) (191.55) (248.02) (242.66) 
NMR -64.45 -175.11 56.94 133.05 173.55 -104.42 -121.37 
(295.55) (184.89) (56.94) (133.05) (173.55) (255.58) (238.63) 
X-Ray -89.34 -186.68 64.79 126.25 193.10 -112.63 -117.04 
(270.66) (173.32) (64.79) (126.25) (193.10) (247.37) (242.96) 
Standard deviation 
overall 65.85 28.03 52.65 21.74 36.35 52.25 22.01 
NMR 11.52 36.77 8.11 16.80 79.97 64.09 14.65 































169D -78.07 -176.59 63.55 130.69 179.76 
1G5K -82.85 -174.78 48.25 87.03 n.a. 
1GJ1 -72.17 -162.88 48.56 147.26 n.a. 
1IV6 -66.57 -271.83 59.20 134.39 288.91 
-67.29 -240.70 57.84 130.30 n.a. 
1J5N -82.37 -164.36 46.16 130.96 23.32 
1KBD -63.72 -173.40 52.36 142.47 187.18 
1KVH -105.07 -134.44 57.43 115.27 n.a. 
1LFU -80.71 -163.04 70.94 146.50 126.00 
1LWA -65.08 -178.95 63.29 112.21 147.46 
1N0K -68.88 -208.61 59.68 134.04 n.a. 
1NOO -70.14 -210.31 71.94 135.98 n.a. 




























PD0005 -224.31 -223.48 178.83 149.72 164.91 -110.82 -116.41 
-93.62 -208.68 63.08 107.37 195.86 -106.46 -159.41 
PD0010 -51.81 -186.86 48.37 144.21 255.55 -171.38 -98.56 
-41.94 -203.85 43.09 141.53 261.24 -176.02 -99.06 
PD0023 -89.32 -186.28 61.04 101.98 154.29 -95.01 -133.61 
-115.32 -158.12 49.94 87.61 137.58 -78.02 -128.57 
PD0024 -63.50 -170.65 38.33 139.60 183.97 -117.25 -104.18 
-60.88 -176.40 40.76 133.61 185.82 -104.61 -108.17 
PD0030 -76.37 -168.02 49.43 81.91 187.94 -75.36 -145.11 
PD0032 -75.64 -168.43 49.78 80.16 188.71 -72.95 -148.43 
PD0033 -85.33 -162.23 49.71 79.59 183.01 -71.48 -145.44 
PD0041 -59.21 -193.36 61.75 138.18 232.85 -52.02 -117.99 
PD0068 -82.52 -192.10 56.72 130.70 229.62 -81.57 -92.56 




-59.56 -198.45 53.22 141.96 170.25 -82.05 -94.74 
PD0105 37.66 -158.31 295.62 153.95 174.01 -84.25 -122.29 
PD0112 -68.09 -181.09 48.18 140.41 204.01 -174.24 -102.57 
-50.09 -202.29 51.05 113.72 n.a. n.a. -136.51 
-57.59 -181.71 40.14 143.70 203.21 -167.57 -99.05 
-57.54 -191.71 48.54 120.08 n.a. n.a. -127.11 
-63.32 -185.39 44.17 142.86 207.04 -176.49 -101.43 
-57.47 -189.01 50.91 117.13 n.a. n.a. -126.43 
-69.92 -180.77 48.61 145.75 205.85 178.74 -97.73 
-54.02 -192.33 50.41 116.38 n.a. n.a. -129.26 
-65.93 -182.95 45.58 144.31 208.62 -178.59 -95.46 
-54.76 -194.21 48.41 123.20 n.a. n.a. -126.18 
PD0145 -145.49 -102.11 74.49 115.65 173.04 -124.77 -99.75 
-71.69 -168.31 53.64 149.81 193.33 -118.17 -104.33 
PD0146 -144.77 -110.53 72.86 107.96 164.32 -102.19 -111.91 
-147.50 -121.58 98.71 113.15 172.10 -116.40 -133.80 
PD0155 -69.77 -172.96 42.57 141.22 202.83 -136.07 -101.70 
-70.40 -182.81 53.84 121.12 194.06 -130.01 -119.60 
PD0165 -63.15 -174.24 41.26 129.13 189.39 -106.93 -105.68 
-330.94 -180.05 299.10 147.11 177.05 -83.24 -105.15 
-69.64 -173.14 40.48 125.10 181.64 -93.17 -102.21 
-83.03 -160.47 49.23 133.06 183.82 -101.78 -106.02 
-79.61 -159.20 44.96 136.01 189.36 -112.34 -108.64 
-64.10 -166.24 38.26 132.11 181.35 -95.30 -104.54 
PD0192 -69.60 -224.20 48.26 141.38 178.63 -109.12 -111.01 
PD0200 -71.50 -202.23 56.89 147.81 185.70 -92.24 -122.07 
PD0219 -64.07 -181.08 53.36 85.84 192.50 -71.54 -160.85 
-54.09 -186.10 47.34 88.50 190.94 -72.67 -162.78 
-52.96 -184.28 42.97 88.06 186.55 -68.38 -160.58 
-71.67 -177.05 56.27 86.46 193.60 -73.89 -161.98 
PD0221 -47.87 -176.05 38.20 138.91 207.53 -108.29 -116.65 
PD0222 -141.12 -228.60 91.85 150.70 207.30 -150.25 -128.75 
PD0230 -333.52 -183.63 -48.11 156.85 174.66 -84.65 -99.47 
PD0231 -65.91 -161.57 40.80 139.19 177.56 -93.36 -102.72 




PD0252 -55.97 -207.22 45.71 143.99 194.35 -134.85 -103.20 
PD0259 -45.11 -200.15 48.07 141.24 173.62 -95.60 -106.76 
-51.80 -197.96 46.24 137.45 175.37 -103.37 -100.86 
PD0270 -41.26 -163.17 22.91 149.25 191.79 -139.44 -108.65 
PD0286 -40.73 -197.44 49.09 140.94 192.57 -144.98 -94.35 
-37.66 -199.04 48.78 143.65 196.26 -121.32 -112.88 
-13.43 -242.35 46.20 140.35 204.76 -165.26 -105.16 
-67.57 -166.20 38.94 140.13 196.91 -145.82 -92.38 
PD0307 •78.84 -223.40 49.52 140.14 207.99 -128.15 -126.63 
-180.56 -123.25 151.75 92.78 196.44 -60.77 -158.18 
PD0309 -239.74 -123.21 181.32 129.10 206.84 -89.40 -151.36 
-49.90 -199.75 60.37 147.99 207.93 -120.36 -94.94 
PD0310 -53.89 -204.75 45.13 140.16 195.72 -121.55 -105.94 
PD0312 -47.96 -178.48 43.86 140.93 n.a. n.a. -114.14 
-49.77 -197.25 36.34 140.38 n.a. n.a. -87.86 
PD0316 -228.61 -188.68 177.14 144.90 180.82 -111.86 -113.01 
-85.94 -145.52 44.25 158.17 147.67 -136.26 -111.77 
PD0319 -73.77 -149.06 46.10 155.80 294.44 -233.06 -83.21 
PD0320 -67.34 -195.60 60.23 167.82 270.54 -206.81 -91.48 
PD0338 -45.98 -205.24 40.58 134.17 169.37 -98.56 -97.68 
PD0364 -8.23 -221.14 25.98 129.74 166.63 -101.31 -111.72 
PD0365 -333.21 -234.76 3.63 131.75 161.61 •100.10 -86.92 
PD0393 -62.53 -181.02 43.68 117.68 58.26 -308.11 -98.70 
-167.94 -153.21 60.20 151.50 314.87 -217.40 -84.67 
-81.88 -212.36 13.14 123.72 156.71 -90.34 -100.82 
-84.44 -164.96 65.94 107.13 160.95 -56.78 -123.53 
-89.13 -170.25 53.20 103.53 170.27 -74.53 -135.09 
PD0424 -48.37 -177.08 33.83 138.89 185.62 -99.05 -109.10 
-81.03 -155.83 44.37 145.27 188.66 -105.17 -94.62 
PD0429 -49.57 -167.74 40.44 137.75 189.12 -118.21 -100.50 
-39.14 -200.09 39.69 138.73 205.76 -158.69 -108.47 
-319.53 -209.10 321.03 151.35 189.73 -77.35 -91.35 
-113.92 -279.15 166.67 146.66 201.71 -90.37 -146.72 
PD0504 -50.27 -218.55 43.44 138.87 191.73 -93.26 -113.56 
-62.05 -179.90 36.44 140.66 199.53 -139.78 -93.56 
89 
(cont'd) 
-40.42 -211.16 38.00 138.35 206.92 -164.87 -107.15 
PD0505 -55.67 -214.24 39.85 137.59 199.79 -98.62 -113.07 
-50.94 -194.24 31.94 134.59 200.08 -155.28 -97.84 
-67.68 -211.86 49.62 139.65 186.90 -91.02 -117.14 
-68.89 -175.69 43.54 140.39 195.25 -128.71 -100.74 
PDE003 -52.90 -191.87 58.45 138.32 221.72 -128.68 -113.80 
-67.38 -189.83 74.76 140.16 216.47 -122.86 -108.80 
PDE011 -68.78 -166.80 56.05 151.15 206.28 -142.30 -107.35 
PDE012 -69.91 -188.01 56.31 142.21 202.50 -127.09 -104.33 
-56.78 -177.64 48.89 141.39 184.44 -124.40 -102.10 
PDE0128 -78.19 -190.22 57.67 73.49 196.67 -64.32 -172.92 
-92.86 -177.49 71.48 76.53 219.43 -93.26 -176.20 
-59.63 -201.64 55.71 67.74 204.36 -61.52 -168.17 
-289.01 -198.60 61.98 73.15 204.04 -88.80 -177.18 




overall -86.67 177.79 60.82 124.16 196.03 -112.94 -119.54 
(273.33) (177.79) (60.82) (124.16) (196.03) (247.06) (240.46) 
NMR -64.45 226.89 56.94 133.06 179.55 -104.42 -121.37 
(295.55) (226.89) (56.94) (133.06) (179.55) (255.58) (238.63) 
X-Ray -89.05 172.53 61.24 123.21 198.17 -114.05 -119.35 
(270.95) (172.53) (61.24) (123.21) (198.17) (245.95) (240.65) 
Standard deviation 
overall 56.61 38.89 38.44 21.64 31.03 37.06 25.37 
NMR 0.69 69.43 5.67 18.08 12.21 8.85 4.10 





1KBD -63.72 186.60 52.36 142.47 187.18 -108.98 -118.80 
1LWA -65.08 307.05 63.29 112.21 165.46 -94.22 -126.10 
2KBD -64.55 187.01 55.19 144.49 186.00 -110.06 -119.22 
PD0068 -82.52 167.90 56.72 130.70 229.62 -81.57 -92.56 
PD0095 -40.91 145.15 48.68 138.86 170.95 -86.19 -94.29 
-59.56 161.55 53.22 141.96 170.25 -82.05 -94.74 
PD0112 -50.09 157.71 51.05 113.72 n.a. n.a. -136.51 
-57.54 168.29 48.54 120.08 n.a. n.a. -127.11 
-57.47 170.99 50.91 117.13 n.a. n.a. -126.43 
-54.02 167.67 50.41 116.38 n.a. n.a. -129.26 
-54.76 165.79 48.41 123.20 n.a. n.a. -126.18 
PD0145 -145.49 257.89 74.49 115.65 173.04 -124.77 -99.75 
PD0146 -144.77 249.47 72.86 107.96 164.32 -102.19 -111.91 
PD0251 -74.61 170.64 52.63 135.95 195.79 -135.47 -103.68 
-66.19 166.05 55.74 135.70 197.05 -123.92 -113.19 
PD0252 -72.72 172.76 45.04 140.14 210.22 -149.12 -97.96 
-55.97 152.78 45.71 143.99 194.35 -134.85 -103.20 
PD0393 -167.94 206.79 60.20 151.50 314.87 -217.40 -84.67 
-81.88 147.64 13.14 123.72 156.71 -90.34 -100.82 
-84.44 195.04 65.94 107.13 160.95 -56.78 -123.53 
-89.13 189.75 53.20 103.53 170.27 -74.53 -135.09 
PD0429 -39.14 159.91 39.69 138.73 205.76 -158.69 -108.47 
-113.92 80.85 166.67 146.66 201.71 -90.37 -146.72 
PD0504 -62.05 180.10 36.44 140.66 199.53 -139.78 -93.56 
-40.42 148.84 38.00 138.35 206.92 -164.87 -107.15 
PD0505 -50.94 165.76 31.94 134.59 200.08 -155.28 -97.84 
-68.89 184.31 43.54 140.39 195.25 -128.71 -100.74 
PDE0128 -92.86 182.51 71.48 76.53 219.43 -93.26 -176.20 
-59.63 158.36 55.71 67.74 204.36 -61.52 -168.17 
-289.01 161.40 61.98 73.15 204.04 -88.80 -177.18 
-236.53 194.86 222.32 125.66 212.55 -82.66 -164.76 
REFERENCES 
1. Dahm, R. Dev. Biol 2005，278�274. 
2. Levene, P. A. J. Biol. Chem. 1919，卯，415. 
3. Astbury, W. T. Symp. Soc. Exp. Biol. (Nucleic Acids), 1947，1, 66. 
4. Watson, J.; Crick, F. Nature 1953，171, 737. 
5. Lehninger, A. L.; Nelson, D. L.; Cox, M. M. Principles of Biochemistry 1993, 2nd 
ed. Worth Publishers, Inc. 
6. Belmont, R; Constant, J. R; Demeunynck, M. Chem. Soc. Rev 2001, 30, 70. 
7. Markley, J. L.; Bax, A.; Arata, Y,; Hilbers，C. W.; Kaptein, R.; Sykes, B. D.; 
Wright, P. E.; Wuthrich, K. Pure & Appl. Chem. 1998, 70，117. 
8. Dickerson, R. E.; Bansal, M.; Calladine, C. R.; Diekmann, S.; Hunter, W. N.; 
Kennard, O.; von Kitzing, E.; Lavery, R.; Nelson, H. C. M.; Olso, W. K.; Saenger, 
W ; Shakked, Z.; Sklenar, H.; Soumpasis, D. M.; Tung, C.-S.; Wang, H. J.; 
Zhurkin, V B. EMBO J. 1989,8, 1. 
9. Saenger, W. Principles of Nucleic Acid Structure 1984, Springer-\ferlag. 
0. Hobza, R; Sponer, J. Chem. Rev. 1999，99, 3247. 
1. Prat, R; Houk, K. N.; Foote, C. S. J. Am. Chem. Soc. 1998，120, 845. 
2. Kino, K.; Saito’ I.; Sugiyama, H. J. Am. Chem. Soc. 1998，120, 7373. 
3. Weatherly, S. C.; Yang, I. V; Thorp, H. H. J. Am. Chem. Soc. 2001, 723, 1236. 
4. Giese, B. Acc. Chem. Res. 2000，33, 631. 
5. Sugiyama, H.; Saito, I. J. Am. Chem. Soc. 1996,118, 7063. 
16. Saito，I.; Takayama, M.; Sugiyama, H.; Nakatani, K. J. Am. Chem. Soc. 1995,117, 
6406. 
17. Yoshioka, Y; Kitagawa, Y; Takano, Y; Yamaguchi, K.; Nakamura, T; Saito, I. J. 
Am. Chem. Soc. 1999，727,8712. 
18. Fu, A.Y.Y. M , Phil. Thesis, The Chinese University of Hong Kong, 2004. 
19. Go, R. S.; Adjei, A. A. J.Clin. Oncol. 1999,17, 409. 
20. Rosenberg, B.; van Camp, L.; Trosko, J. L; Mansour, V H. Nature 1969，222,385. 
21. Matsui, T.; Shigeta，Y.; Hirao, K. J. Phys. Chem. B 2007，111, 1176. 
22. Jamieson, E. R.; Lippard, S. J. Chem. Rev. 1999, 99, 2467. 
23. Fuertes, M. A.; Alonso，C; Perez, J. M. Chem. Rev. 2003，103, 645. 
24. Baik, M.; Friesner, R. A.; Lippard, S. J. J. Am. Chem. Soc. 2003，125, 14082. 
25. Spiegel, K.; Rothlisbergeer, U.; Carloni, P. J. Phys. Chem. 5 2004,108, 2699. 
26. Yang, X. L.; Wang, A. H.-J. J. Pharmacol Ther. 1999, 83, 181. 
27. Eastman, A. Biochemistry 1986, 25, 3912. 
28. Admiraal, G; Alink, M.; Altona, C.; Dijt, F. J.; van Garderen, C. J•； de Graaff, R. 
A. G; Reedijk, J. J. Am. Chem. Soc. 1992,114, 930. 
29. Davies, M. S.; Bemers-Price, S. J.; Hambley, T. W. J. Am. Chem. Soc. 1998，120, 
11380. 
30. Wang, K.; Yu, Y. X.; Gao, G.-H.; Luo, G-S. J. Chem. Phys. 2005，725,1. 
31. Skylaris, C. K.; Haynes, P. D.; Mostofi, A. A.; Payne, M. C. Phys. Stat. Sol. B 
2006，243’ 973. 
32. Raugei, S.; Gervasio, F. L.; Carloni, P. Phys. Stat. Sol. B 2006，243, 2500. 
33. Canfield, P.; Dahlbom, M. G; Hush, N. S.; Reimers, J. R. J. Chem. Phys. 2006, 
124, 1. 
34. McNamara, J. P.; Hillier, I. H. Phys. Chem. Chem. Phys. 2007, 9，2362. 
35. Sha, S.; Roy, R. K. J. Phys. Chem. B 2007，111, 9664. 
36. Troisi, A.; Orlandi, G J. Phys. Chem. B, 2002，106, 2093. 
37. van der Vaart, A.; Merz, Jr. K. M. J. Chem. Phys. 2002,116, 7380. 
38. Habza, R; Sponer, J. Chem. Rev. 1999, 99, 3247. 
39. Foresman, J. B. Exploring Chemistry with Electronic Structure Methods, 1996, 
2nd ed., Gaussian, Inc. 
40. Case, D. A.; Ill, T. E. C.; Tom Darden, H. G; Luo, R.; Jr., K. M. M•； Onufriev, A.; 
Simmerling, C.; Wang, B.; Woods, R. J. J. Comput. Chem. 2005, 26, 1668. 
41. Zilberberg, 1. L.; Avdeev, V. I.; Zhidomirov, G M. J. Mol. Struc. (Theochem). 
1997，418, 73. 
42. Pelmenschikov, A.; Zilberberg, I.; Leszczynski, J. et al. Chem. Phys. Lett. 1999, 
314, 496. 
43. Zeizinger, M.; Burda, J. V.; Leszczynski, J. Phys. Chem. Chem. Phys. 2004，6, 
3585. 
44. Qin, H.; Li-Xin, Z.; Zhi-Qiang, Z. Chin. J. Chem. 2005, 23, 1355. 
45. Kitaura, K.; Sawai, T.; Asada, T.; Nakano, T.; Uebayasi, M. Chem. Phys. Lett. 
1999，5/2,319. 
46. Kitaura, K.; Sawai, T.; Asada, T.; Nakano, T.; Uebayasi, M. Chem. Phys. Lett. 
1999, 513, 701. 
- 9 4 -
47. Takeshi, I.; Yuji, M.; Tatsuya, N. et al Chem. Phys. Lett. 2006，427, 159. 
48. Frisch, M. J.; Trucks, G W.; Schlegel, H. B.; Scuseria, G E.; Robb, M. A.; 
Cheeseman, J. R.; Montgomery, J. A.; Vreven, Jr. T; Kudin, K. N.; Burant, J. C.; 
Millam, J. M.; Iyengar, S. S.; Tomasi, J.; Barone, V; Mennucci, B.; Cossi, M.; 
Scalmani, G; Rega, N.; Petersson, G A.; Nakatsuji, H.; Hada, M.; Ehara, M.; 
Toyota, K.; Fukuda, R.; Hasegawa, J.; Ishida, M.; Nakajima, T; Honda, Y; Kitao, 
O.; Nakai, H.; Klene, M.; Li, X.; Knox, J. E.; Hratchian, H. R; Cross, J. B.; 
Adamo, C.; Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin, A. J.; 
Cammi, R.; Pomelli, C.; Ochterski, J. W ; Ayala, R Y; Morokuma, K.; \6th, G A.; 
Salvador, R; Dannenberg, J. J.; Zakrzewski, V G; Dapprich, S.; Daniels, A. D.; 
Strain, M. C.; Farkas, O.; Malick, D. K.; Rabuck, A. D.; Raghavachari, K.; 
Foresman, J. B.; Ortiz, J. V; Cui, Q.; Baboul, A. G; Clifford, S.; Cioslowski, J.; 
Stefanov, B. B.; Liu, G; Liashenko, A.; Piskorz, R; Komaromi, I.; Martin, R. L.; 
Fox, D. J.; Keith, T; Al-Laham, M. A.; Peng, C. Y.; Nanayakkara, A.; 
Challacombe, M.; Gill, R M. W ; Johnson, B.; Chen, W ; Wong, M. W ; Gonzalez, 
C.; Pople，J. A. Gaussian 03, revision B.04; Gaussian, Inc., Pittsburgh PA, 2003. 
49. Berman, H. M.; Olson, W. K.; Beveridge, D. L.; Westbrook, J.; Gelbin, A.; 
Demeny, T; Hsieh, S. H.; Srinivasan, A. R.; Schneider, B. Biophys. J., 1992, 63, 
751. 
50. N D B ID: PD0005, PDOOlO, PD0023, PD0024, PD0030, PD0032, PD0033, 
PD0041, PD0068, PD0095, PD0105, PD0112, PD0145, PD0146, PD0155, 
PD0165, PD0192, PD0200, PD0219, PD0221, PD0222, PD0230, PD0231, 
PD0251, PD0252, PD0259, PD0270, PD0286, PD0307, PD0309, PD0310, 
PD0312, PD0316, PD0319, PD0320, PD0338, PD0364, PD0365, PD0393, 
PD0424, PD0429, PD0504, PD0505, PDE003, PDEOll, PDE012, PDE0128. 
51. N D B ID: 169D，1G5K, IGJl, 1IV6, 1J5N, IKBD, IKVH, ILFU, ILWA, 
INOK, INOO and 2KBD. 
52. SYBYL, version 6.2; Tripos Inc.: Missouri, 1995. 
53. Raber, J.; Zhu, C.; Eriksson, L.A. J, Phys. Chem. B 2005，109, 11006. 
54. Rak, J.; Voityuk, A. A.; Marquez, A.; Rosch, N. J. Phys. Chem. B 2002，106, 
7919. 
55. Guallar, V.; Douhal, A.; Moreno, M.; Lluch, J. M. J. Am. Chem. Soc. 1999, 103, 
6251. 
s 
56. Guerra, C. F.; Bickelhaupt, F. M.; Snijders, J. G; Baerends, E. J. Chem. Eur. J. 
1999，5,3581. 
57. Stephan, R.; Christel, M. M. J. Comput. Chem. 2007, 28, 1503. 
58. Tom, M.; Yasuteru, S.; Kimihiko, H. J. Phys. Chem. B 2007, 111, 1176. 
59. Alessandro, T.; Giorgio, O. J. Phys. Chem. B 2002，106, 2093. 
60. Mark, P. W.; Arturo, R.; James, A. P. et al. J. Comput Chem. 2006, 27, 491. 
61. Huheey, J. E.; Keiter, E. A.; Keiter, R. L. Inorganic chemistry: principles of 
structure and reactivity 1993, 4th ed.. New York: HarperCollins College 
Publishers. 
62. Bellon, S. R; Coleman, J. H.; Lippard, S. J. Biochemistry, 1991, 30, 8026. 
63. Pil, R M.; Lippard, S. J. Science, 1992, 256’ 234. 
- 9 6 -
64. Moggs, J. G; Szymkowski, D. E.; Yamada, M.; Karran, R; Wood, R. D. Nucleic 
Acids Res. 1997, 25, 480. 
65. Lavery’ R.; Sklenar, H. CURVES 4.1, 1992，Institut de Biologic Physico-
Chimique, Paris. 
66. Lavery, R.; Sklenar, H. J. Biomol. Struct. Dynam. 1988, 6’ 63. 
67. Lavery, R.; Sklenar, H. J. Biomol. Struct. Dynam. 1989，6, 655. 
68. Wilkdns, M. H. R; Randall, J. T.Biochim. etBiophys. Acta. 1953,10,192. 
69. Fichtinger-Schepman, A. M. J.; van der Veer, J. L.; den Hartog, J. H. J.; Lohman, 
P. H. M.; Reedijk, J. Biochemistry, 1985，24’ 707. 
70. N D B ID: N M R : 169D, 1J5N, ILFU; X-Ray: PD0024, PD0030, PD0033, PD0112, 
PD0222, PD0393，PD0504，PD0505, PDE003. 
97. 

C U H K L i b r a r i e s 
004659977 
